[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4456
1. Türe-Ozdemir F, Gazouli M, Tzivras M, Panagos C, Bovaretos N, Petraki K, Giannakopoulos A, Korkolopoulou P, Mantzaris GJ: Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer Res; 2008 Nov-Dec;28(6A):3697-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma.
  • A genetic risk profile for gastric cancer has been identified, but genetic susceptibility to develop gastric mucosa-associated lymphoid tissue (MALT) lymphoma is unclear.
  • The aim of this study was to evaluate the relationship between NOD2, TLR4 and CD14 genetic polymorphisms and the development of gastric MALT-lymphoma.
  • MATERIALS AND METHODS: Fifty-six patients with primary gastric MALT lymphoma and 51 patients with H. pylori infection were enrolled in this study.
  • RESULTS: No polymorphisms in the NOD2 and TLR4 genes were found to be associated with the development of gastric MALT lymphoma.
  • Carriers of the CD14 gene -159T allele had a marginally increased risk of developing gastric MALT lymphoma than the controls (p=0.042).
  • CONCLUSION: The -159C/T genetic polymorphism of the CD14 gene may be implicated in the development of gastric MALT lymphoma.
  • [MeSH-major] Antigens, CD14 / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Nod2 Signaling Adaptor Protein / genetics. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189651.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  •  go-up   go-down


2. Lobetti-Bodoni C, Bernocco E, Genuardi E, Boccadoro M, Ladetto M: Telomeres and telomerase in normal and malignant B-cells. Hematol Oncol; 2010 Dec;28(4):157-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The telomeric checkpoint is emerging as a critical sensor of cellular damage, playing a major role in human aging and cancer development.
  • In the meantime, telomere biology is rapidly evolving from a basic discipline to a translational branch, capable of providing major hints for biomarker development, risk assessment and targeted treatment of cancer.
  • [MeSH-minor] Aging / genetics. Animals. Cell Aging / genetics. Humans. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Models, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20213664.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


3. Maloney DG: Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Semin Oncol; 2005 Feb;32(1 Suppl 1):S19-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunotherapy became a feasible therapeutic approach following the development of monoclonal antibody technology.
  • CD20 is expressed on B cells, and rituximab has been widely used in the treatment of various histologies of B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Lymphoma, B-Cell / drug therapy. Radioimmunotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786022.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Receptors, Fc; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Babbe H, McMenamin J, Hobeika E, Wang J, Rodig SJ, Reth M, Leder P: Genomic instability resulting from Blm deficiency compromises development, maintenance, and function of the B cell lineage. J Immunol; 2009 Jan 1;182(1):347-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability resulting from Blm deficiency compromises development, maintenance, and function of the B cell lineage.
  • Finally, a cohort of p53-deficient, conditional Blm knockout mice revealed an increased propensity for B cell lymphoma development.
  • Collectively, our data highlight the importance of BLM-dependent genome surveillance for B cell immunity by ensuring proper development and function of the various B cell subsets while counteracting lymphomagenesis.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1993 Feb 11;21(3):365-72 [8441648.001]
  • [Cites] J Biol Chem. 1993 Sep 25;268(27):20105-9 [8397200.001]
  • [Cites] Medicine (Baltimore). 1993 Nov;72(6):393-406 [8231788.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):176-83 [8254190.001]
  • [Cites] Int Immunol. 1994 Apr;6(4):491-7 [8018590.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Immunity. 1995 Jul;3(1):39-50 [7542548.001]
  • [Cites] Cell. 1995 Nov 17;83(4):655-66 [7585968.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):2055-66 [8769648.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):100-6 [9062585.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27587-92 [9765292.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3382-93 [9808625.001]
  • [Cites] Immunity. 1999 May;10(5):493-502 [10367895.001]
  • [Cites] J Exp Med. 2004 Nov 1;200(9):1111-21 [15504820.001]
  • [Cites] J Exp Med. 2004 Nov 1;200(9):1103-10 [15520243.001]
  • [Cites] Springer Semin Immunopathol. 2005 Mar;26(4):347-62 [15633017.001]
  • [Cites] Annu Rev Immunol. 2005;23:367-86 [15771575.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):201-14 [16427010.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2119-23 [16288211.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22839-46 [16766518.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6713-26 [16914751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13789-94 [16940357.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1947-59 [17210642.001]
  • [Cites] Genes Dev. 2007 Dec 1;21(23):3073-84 [18003859.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(17):2306-22 [17571213.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Immunity. 1999 Nov;11(5):547-54 [10591180.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):23-32 [10620602.001]
  • [Cites] Clin Exp Immunol. 2000 Jul;121(1):1-7 [10886231.001]
  • [Cites] Immunol Rev. 2000 Jun;175:158-74 [10933601.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):424-9 [11101838.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] Nat Rev Genet. 2001 Mar;2(3):196-206 [11256071.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):2843-9 [11433031.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):32948-55 [11399766.001]
  • [Cites] Nucleic Acids Res. 2001 Nov 1;29(21):4378-86 [11691925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14553-8 [11717399.001]
  • [Cites] Trends Immunol. 2002 Jan;23(1):31-9 [11801452.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):367-73 [11828012.001]
  • [Cites] Annu Rev Immunol. 2002;20:253-300 [11861604.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):323-35 [12033738.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30515-23 [12034743.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):35-47 [12427530.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1210-22 [12606585.001]
  • [Cites] Annu Rev Immunol. 2003;21:71-105 [12414721.001]
  • [Cites] Curr Opin Immunol. 2003 Jun;15(3):354-61 [12787764.001]
  • [Cites] Immunol Rev. 2003 Aug;194:77-95 [12846809.001]
  • [Cites] Cell. 2003 Aug 8;114(3):359-70 [12914700.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Biochem J. 2003 Sep 15;374(Pt 3):577-606 [12803543.001]
  • [Cites] J Cell Biol. 2003 Sep 29;162(7):1197-209 [14517203.001]
  • [Cites] DNA Repair (Amst). 2003 Dec 9;2(12):1387-404 [14642567.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):870-4 [14685245.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1279-91 [14729972.001]
  • [Cites] J Cell Biol. 2004 May 24;165(4):459-64 [15159415.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):541-52 [15229473.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1618-29 [15231739.001]
  • [Cites] Nat Genet. 2004 Aug;36(8):877-82 [15235603.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8437-46 [15367665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Feb;72(2):758-62 [1054854.001]
  • [Cites] J Clin Invest. 1975 Jul;56(1):1-7 [124745.001]
  • [Cites] Am J Dis Child. 1988 Oct;142(10):1089-93 [3263039.001]
  • [Cites] J Clin Lab Immunol. 1989 Mar;28(3):151-4 [2525624.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3141-5 [2110504.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4781-4 [2352948.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Curr Opin Immunol. 1991 Apr;3(2):179-85 [2069745.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Acta Paediatr. 1992 Jan;81(1):86-90 [1600313.001]
  • (PMID = 19109166.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI054636-01; United States / NIAID NIH HHS / AI / R37 AI054636; United States / NIAID NIH HHS / AI / R37 AI054636-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Isotypes; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.4.12 / RecQ Helicases
  • [Other-IDs] NLM/ NIHMS85515; NLM/ PMC2742995
  •  go-up   go-down


5. Elter T, Stipanov M, Heuser E, von Bergwelt-Baildon M, Bloch W, Hallek M, Baumann F: Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma? Int J Hematol; 2009 Sep;90(2):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?
  • Patients undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma not only suffer from the direct side effects of chemotherapy such as infections due to long-lasting immuno-suppression and aplasia, but also from marked fatigue and the inability to do normal physical activity.
  • This leads to a vicious cycle of losing physical strength and muscle with subsequent development of treatment-related cachexia and an increased treatment mortality.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Exercise Therapy. Leukemia / drug therapy. Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1539-49 [10735903.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3390-4 [9345021.001]
  • [Cites] J Psychosom Res. 2000 Jan;48(1):11-21 [10750625.001]
  • [Cites] Oncol Nurs Forum. 1994 Jun;21(5):899-907; discussion 908 [7937251.001]
  • [Cites] Support Care Cancer. 2003 Oct;11(10):623-8 [12942360.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3535-41 [16822843.001]
  • [Cites] Phys Sportsmed. 1986 Oct;14(10):125-34 [27432137.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3517-8 [16822842.001]
  • [Cites] Z Kardiol. 2000 Sep;89(9):821-31 [11077695.001]
  • [Cites] Rehabilitation (Stuttg). 1983 Feb;22(1):36-9 [6836164.001]
  • [Cites] CMAJ. 2006 Jul 4;175(1):34-41 [16818906.001]
  • [Cites] JAMA. 2005 May 25;293(20):2479-86 [15914748.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3A):1033-6 [8074446.001]
  • [Cites] Psychooncology. 1999 Jan-Feb;8(1):64-73 [10202784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1157-60 [8971388.001]
  • [Cites] Bone Marrow Transplant. 1989 Sep;4(5):505-9 [2790328.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):677-82 [12139764.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3527-34 [16822844.001]
  • [Cites] Bone Marrow Transplant. 1998 Mar;21(5):477-86 [9535040.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):723-8 [13130321.001]
  • [Cites] Br J Sports Med. 2004 Dec;38(6):e37 [15562152.001]
  • (PMID = 19629631.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer; 2007 Nov;7(11):834-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Models, mechanisms and clinical evidence for cancer dormancy.
  • Patients with cancer can develop recurrent metastatic disease with latency periods that range from years even to decades.
  • This pause can be explained by cancer dormancy, a stage in cancer progression in which residual disease is present but remains asymptomatic.
  • Cancer dormancy is poorly understood, resulting in major shortcomings in our understanding of the full complexity of the disease.
  • Here, I review experimental and clinical evidence that supports the existence of various mechanisms of cancer dormancy including angiogenic dormancy, cellular dormancy (G0-G1 arrest) and immunosurveillance.
  • The advances in this field provide an emerging picture of how cancer dormancy can ensue and how it could be therapeutically targeted.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):472-6 [16723993.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3882-9 [16818682.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):630-4 [16627982.001]
  • [Cites] Nat Med. 2006 Aug;12(8):933-8 [16862154.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7849-53 [16912156.001]
  • [Cites] Science. 2006 Aug 18;313(5789):971-5 [16917064.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):729-35 [16861922.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1788-98 [16929175.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1772-8 [16929181.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5606-7 [17020960.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5615-21 [17020963.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93 [17062670.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 2;270(1):108-11 [10733912.001]
  • [Cites] Recent Results Cancer Res. 2001;158:14-24 [11092029.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):96-105 [11279612.001]
  • [Cites] Mol Biol Cell. 2001 Apr;12(4):863-79 [11294892.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5575-9 [11454710.001]
  • [Cites] J Urol. 2001 Aug;166(2):699-703 [11458120.001]
  • [Cites] Semin Cancer Biol. 2001 Aug;11(4):271-6 [11513562.001]
  • [Cites] Bull Cancer. 2007 Sep;94(9):753-62 [17878094.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1496-504 [17881897.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R16 [16563182.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2124-33 [15191948.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7336-45 [15492254.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] J Exp Med. 1979 Mar 1;149(3):732-44 [311815.001]
  • [Cites] J Exp Med. 1979 Mar 1;149(3):745-57 [429962.001]
  • [Cites] Science. 1982 Jul 23;217(4557):361-3 [6953592.001]
  • [Cites] J Cell Sci. 1985 Feb;73:375-87 [3894388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(16):5365-9 [3860868.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):303-9 [1879974.001]
  • [Cites] J Clin Invest. 1994 Oct;94(4):1383-9 [7929813.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] N Engl J Med. 1997 Jan 30;336(5):317-23 [9011783.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1394-9 [9102229.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5439-46 [9850077.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):55-63 [12509767.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Urol. 2003 Mar;169(3):1122-33 [12576866.001]
  • [Cites] Development. 2003 Apr;130(8):1621-34 [12620986.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):199-200 [12676576.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):219-31 [12676581.001]
  • [Cites] Clin Breast Cancer. 2003 Apr;4(1):51-62 [12744759.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2705-15 [12782571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42 [12808139.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] J Chemother. 2003 Oct;15(5):495-502 [14598943.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):199-206 [14703067.001]
  • [Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):227-35 [14993904.001]
  • [Cites] Genetics. 2004 May;167(1):161-70 [15166144.001]
  • [Cites] Science. 2004 May 28;304(5675):1338-40 [15060285.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Acta Haematol. 2004;112(1-2):111-9 [15179011.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5193-9 [15289324.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):159-70 [15324699.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2264-70 [16489030.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):141-6 [16491073.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] PLoS Biol. 2006 Mar;4(3):e83 [16509772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4216-21 [16537511.001]
  • [Cites] Curr Biol. 2006 Apr 18;16(8):773-9 [16631584.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1309-13 [16686730.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14852-63 [16547007.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):80-5 [9890174.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2842-9 [10072532.001]
  • [Cites] Histol Histopathol. 1999 Apr;14(2):561-9 [10212818.001]
  • [Cites] J Cell Sci. 1999 Jun;112 ( Pt 12):1835-42 [10341203.001]
  • [Cites] Science. 1999 Jul 9;285(5425):245-8 [10398599.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):101-8 [10505549.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):109-26 [10505550.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):89-104 [10508858.001]
  • [Cites] Adv Cancer Res. 2004;92:95-118 [15530558.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8152-62 [15623589.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):182-6 [15640797.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Mech Ageing Dev. 2005 Jun-Jul;126(6-7):642-7 [15888317.001]
  • [Cites] Immunology. 2005 Jul;115(3):325-36 [15946250.001]
  • [Cites] Nature. 2005 Sep 1;437(7055):141-6 [16136144.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):227-39 [16169467.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1055-62 [16142231.001]
  • [Cites] Dev Cell. 2005 Nov;9(5):605-15 [16256736.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10984-91 [16322247.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1702-11 [16452230.001]
  • [Cites] Semin Cancer Biol. 2001 Aug;11(4):297-306 [11513565.001]
  • [Cites] Semin Cancer Biol. 2001 Aug;11(4):307-11 [11513566.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):195-202 [11531779.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):673-9 [11535128.001]
  • [Cites] Nat Med. 2000 Jan;6(1):100-2 [10613833.001]
  • [Cites] Mol Pharmacol. 2001 Nov;60(5):900-6 [11641417.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):933-44 [11697648.001]
  • [Cites] Semin Surg Oncol. 2001 Jun;20(4):278-81 [11747269.001]
  • [Cites] Semin Surg Oncol. 2001 Jun;20(4):282-93 [11747270.001]
  • [Cites] Semin Surg Oncol. 2001 Jun;20(4):294-303 [11747271.001]
  • [Cites] Semin Surg Oncol. 2001 Jun;20(4):319-28 [11747274.001]
  • [Cites] Blood. 2002 Jan 15;99(2):507-12 [11781231.001]
  • [Cites] Curr Opin Plant Biol. 2002 Feb;5(1):33-6 [11788305.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2162-8 [11929839.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2005-16 [11956259.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2513-24 [11971186.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):445-57 [12124174.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Curr Biol. 2002 Sep 3;12(17):1448-61 [12225660.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):451-61 [12498714.001]
  • [Cites] Magn Reson Med. 2006 Nov;56(5):1001-10 [17029229.001]
  • [Cites] J Virol. 2006 Nov;80(22):11409-15 [16971449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 [17056717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5 [17079488.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2703-13 [16931772.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):195-207 [17060457.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1465-71 [17205532.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):309-21 [17312308.001]
  • [Cites] Immunol Res. 2006;36(1-3):73-82 [17337768.001]
  • [Cites] J Mol Diagn. 2007 Apr;9(2):237-41 [17384216.001]
  • [Cites] Adv Cancer Res. 2007;97:189-202 [17419946.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3734-40 [17440086.001]
  • [Cites] Nat Cell Biol. 2007 May;9(5):493-505 [17450133.001]
  • [Cites] Urol Oncol. 2007 May-Jun;25(3):214-20 [17483018.001]
  • [Cites] Front Biosci. 2007;12:3000-9 [17485277.001]
  • [Cites] Nature. 2007 Jul 19;448(7151):375-9 [17637672.001]
  • (PMID = 17957189.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109182-02; United States / NCI NIH HHS / CA / R01 CA109182-01A1; United States / NCI NIH HHS / CA / CA109182; United States / NCI NIH HHS / CA / R01 CA109182; United States / NCI NIH HHS / CA / R01 CA109182-04; United States / NCI NIH HHS / CA / R01 CA109182-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 140
  • [Other-IDs] NLM/ NIHMS53903; NLM/ PMC2519109
  •  go-up   go-down


7. Chaiworapongsa T, Kusanovic JP, Savasan ZA, Mazaki-Tovi S, Kim SK, Vaisbuch E, Tarca AL, Mittal P, Ogge G, Madan I, Dong Z, Yeo L, Hassan SS, Romero R: Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. J Matern Fetal Neonatal Med; 2010 Sep;23(9):960-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular endothelial growth factor (VEGF), an indispensible angiogenic factor for embryonic and placental development exerts its angiogenic properties through the VEGF receptor (VEGFR)-2.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1996 Feb;87(2):163-8 [8559516.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):435-9 [8602241.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 13;226(2):324-8 [8806634.001]
  • [Cites] J Soc Gynecol Investig. 1997 Jul-Aug;4(4):169-77 [9292845.001]
  • [Cites] Cell Growth Differ. 1998 Jan;9(1):49-58 [9438388.001]
  • [Cites] J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23 [18175241.001]
  • [Cites] J Matern Fetal Neonatal Med. 2008 Jan;21(1):25-40 [18175242.001]
  • [Cites] J Matern Fetal Neonatal Med. 2008 Jan;21(1):41-52 [18175243.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):536-45 [18032692.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Mar;31(3):303-9 [18058842.001]
  • [Cites] Melanoma Res. 2006 Oct;16(5):405-11 [17013089.001]
  • [Cites] J Matern Fetal Neonatal Med. 2006 Oct;19(10):607-13 [17118734.001]
  • [Cites] Clin Sci (Lond). 2007 Jan;112(1):51-7 [16928195.001]
  • [Cites] Hypertension. 2007 Jan;49(1):15-6 [17116760.001]
  • [Cites] Obstet Gynecol. 2007 Jan;109(1):144-51 [17197600.001]
  • [Cites] Obstet Gynecol. 2007 Jan;109(1):153-67 [17197601.001]
  • [Cites] J Virol. 2007 Feb;81(4):1592-600 [17151115.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):239.e1-6 [17346536.001]
  • [Cites] Am J Obstet Gynecol. 2007 May;196(5):433-44 [17466694.001]
  • [Cites] Obstet Gynecol. 2007 Jun;109(6):1368-74 [17540809.001]
  • [Cites] J Matern Fetal Neonatal Med. 2007 Jul;20(7):495-507 [17674262.001]
  • [Cites] Am J Obstet Gynecol. 2007 Aug;197(2):211.e1-4 [17689655.001]
  • [Cites] Curr Vasc Pharmacol. 2007 Oct;5(4):266-75 [17979793.001]
  • [Cites] Lancet. 2007 Nov 17;370(9600):1715-25 [18022035.001]
  • [Cites] Obstet Gynecol. 2000 Mar;95(3):353-7 [10711543.001]
  • [Cites] Am J Obstet Gynecol. 2001 Nov;185(5):1130-6 [11717646.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Feb;43(2):474-82 [11818393.001]
  • [Cites] BJOG. 2002 Jul;109(7):836-9 [12135223.001]
  • [Cites] J Matern Fetal Neonatal Med. 2002 Jul;12(1):19-27 [12422905.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jan;188(1):177-82 [12548214.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):649-58 [12618519.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):786-93 [12634658.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2348-51 [12727995.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5555-63 [14602804.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):317-29 [14724562.001]
  • [Cites] Mediators Inflamm. 2003 Oct;12(5):293-8 [14760936.001]
  • [Cites] N Engl J Med. 2004 Feb 12;350(7):672-83 [14764923.001]
  • [Cites] J Soc Gynecol Investig. 2004 Feb;11(2):63-74 [14980307.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Jun 15;114(2):162-5 [15140509.001]
  • [Cites] Mol Cancer Res. 2004 Jun;2(6):315-26 [15235107.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jun;190(6):1541-7; discussion 1547-50 [15284729.001]
  • [Cites] Eur J Clin Invest. 1983 Aug;13(4):289-96 [6193964.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):382.e1-8 [18395032.001]
  • [Cites] BJOG. 2008 May;115(6):780-4 [18355365.001]
  • [Cites] J Matern Fetal Neonatal Med. 2008 May;21(5):279-87 [18446652.001]
  • [Cites] BMB Rep. 2008 Apr 30;41(4):278-86 [18452647.001]
  • [Cites] Circ Res. 2008 Oct 24;103(9):916-8 [18818406.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Dec;32(7):871-6 [18814185.001]
  • [Cites] Int J Mol Med. 2009 Jan;23(1):49-55 [19082506.001]
  • [Cites] Oncol Rep. 2009 Apr;21(4):933-9 [19287991.001]
  • [Cites] Atherosclerosis. 2009 Jul;205(1):244-50 [19022445.001]
  • [Cites] J Matern Fetal Neonatal Med. 2010 Feb;23(2):167-78 [20213923.001]
  • [Cites] Am J Obstet Gynecol. 2010 Jun;202(6):550.e1-10 [20510958.001]
  • [Cites] Br J Obstet Gynaecol. 1998 May;105(5):524-30 [9637122.001]
  • [Cites] Semin Reprod Endocrinol. 1998;16(1):5-15 [9654603.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1539-44 [9855593.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1346-51 [10325292.001]
  • [Cites] Br J Obstet Gynaecol. 1999 Oct;106(10):1019-22 [10519425.001]
  • [Cites] Rev Med Chil. 2004 Oct;132(10):1155-65 [15631202.001]
  • [Cites] Hematology. 2005 Apr;10(2):131-4 [16019458.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 1;1751(1):110-7 [16054021.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1345-51 [16109613.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Sep 1;122(1):33-9 [15935542.001]
  • [Cites] Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):984-9 [16157098.001]
  • [Cites] Am J Obstet Gynecol. 2005 Dec;193(6):1923-35 [16325593.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4303-7 [16123221.001]
  • [Cites] J Leukoc Biol. 2006 Jun;79(6):1105-16 [16565325.001]
  • [Cites] Nat Med. 2006 Jun;12(6):642-9 [16751767.001]
  • [Cites] Am J Obstet Gynecol. 2006 Jul;195(1):255-9 [16813756.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):338-44 [16880304.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):992-1005 [16957146.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Jul;94(7):649-55 [3620413.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):62-6 [7596435.001]
  • (PMID = 20158395.001).
  • [ISSN] 1476-4954
  • [Journal-full-title] The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • [ISO-abbreviation] J. Matern. Fetal. Neonatal. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HD002400-19
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ NIHMS395388; NLM/ PMC3427783
  •  go-up   go-down


8. Bello C, Sotomayor EM: Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program; 2007;:233-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also discuss the new generation of monoclonal antibodies, the development of which has been spurred by the widespread success of anti-CD20 MAb therapy.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024635.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 60
  •  go-up   go-down


9. Kovács L, Szodoray P, Kiss E: Secondary tumours in Sjögren's syndrome. Autoimmun Rev; 2010 Feb;9(4):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequent association of Sjögren's syndrome (SS) with non-Hodgkin's B cell lymphoma (NHL) provides an example of the interplay of systemic autoimmunity and lymphoproliferative diseases, and an opportunity to study the pathogenetic steps of lymphomagenesis.
  • Parotidomegaly, lymphadenopathy, inflammatory neuropathy and vasculitis have been found to be predictive of the development of lymphoma.
  • The typical histological type of NHL in SS is a low-grade extranodal marginal zone B cell lymphoma.
  • Recent results indicating the pathogenetic role of ectopic germinal centre formation in the involved exocrine glands, the potential importance of an antigen-driven clonal proliferation of autoreactive B-lymphocytes, the proposed role of the B-lymphocyte activating factor (BAFF) and of further cytokines and, finally, the changes of the chemokine milieu at the site of lymphoma development are highlighted.
  • [MeSH-major] B-Cell Activating Factor / immunology. B-Lymphocytes / immunology. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / immunology. Rheumatoid Factor / immunology. Sjogren's Syndrome / complications. Sjogren's Syndrome / immunology

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19602455.001).
  • [ISSN] 1873-0183
  • [Journal-full-title] Autoimmunity reviews
  • [ISO-abbreviation] Autoimmun Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 9009-79-4 / Rheumatoid Factor
  • [Number-of-references] 40
  •  go-up   go-down


10. Bogunovic M, Ginhoux F, Wagers A, Loubeau M, Isola LM, Lubrano L, Najfeld V, Phelps RG, Grosskreutz C, Scigliano E, Frenette PS, Merad M: Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med; 2006 Nov 27;203(12):2627-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the role of residual host tissue DCs in transplant immune reactions, these results suggest that dermal DC homeostasis may contribute to the development of cutaneous graft-versus-host disease in clinical transplantation.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1987 Jan;16(1 Pt 1):61-74 [3100584.001]
  • [Cites] Curr Top Pathol. 1989;79:101-24 [2644081.001]
  • [Cites] J Invest Dermatol. 1989 Oct;93(4):443-8 [2778349.001]
  • [Cites] Br J Dermatol. 1989 Oct;121(4):421-31 [2576222.001]
  • [Cites] Pathol Biol (Paris). 2003 Mar;51(2):61-3 [12801801.001]
  • [Cites] Blood. 2003 Jul 15;102(2):756-62 [12663454.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9 [12869959.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):283-90 [12927568.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1548-56 [14576063.001]
  • [Cites] Nat Med. 2004 May;10(5):510-7 [15098028.001]
  • [Cites] Int Immunol. 2004 Jun;16(6):877-87 [15113774.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7393-8 [15187116.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):876-9 [15482474.001]
  • [Cites] Nature. 1979 Nov 15;282(5736):324-6 [503208.001]
  • [Cites] J Immunol. 1991 Feb 15;146(4):1192-7 [1899440.001]
  • [Cites] N Engl J Med. 1991 Mar 7;324(10):667-74 [1994250.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] Annu Rev Immunol. 1992;10:759-83 [1375474.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):27-33 [16390938.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):265-73 [16444257.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):311-7 [16462739.001]
  • [Cites] Semin Immunol. 2005 Aug;17(4):273-83 [15953735.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1577-86 [10550315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5 [10588729.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Immunity. 2000 Jan;12(1):71-81 [10661407.001]
  • [Cites] Immunity. 2000 May;12(5):495-503 [10843382.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):705-18 [10974036.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6762-70 [11120796.001]
  • [Cites] Int Immunol. 2001 Jan;13(1):95-103 [11133838.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1263-70 [11290544.001]
  • [Cites] Ann Clin Lab Sci. 2001 Jan;31(1):103-7 [11314859.001]
  • [Cites] J Pathol. 2001 Aug;194(4):398-405 [11523046.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1933-6 [11729320.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1676-82 [11861283.001]
  • [Cites] Arch Dermatol Res. 2002 Jan;293(11):552-9 [11876523.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1335-44 [12021249.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1734-41 [12176895.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1903-9 [12176915.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3108-14 [12384406.001]
  • [Cites] Nat Immunol. 2002 Dec;3(12):1135-41 [12415265.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):7111-8 [12471148.001]
  • [Cites] Adv Exp Med Biol. 1993;329:243-9 [8379377.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2587-96 [8254016.001]
  • [Cites] J Immunol. 1994 Jul 1;153(1):256-61 [8207240.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):202-9 [8040262.001]
  • [Cites] J Invest Dermatol. 1994 Nov;103(5):678-83 [7963656.001]
  • [Cites] J Invest Dermatol. 1995 Jan;104(1):11-7 [7798627.001]
  • [Cites] Life Sci. 1996;58(18):1485-507 [8649179.001]
  • [Cites] Bone Marrow Transplant. 1996 Jun;17(6):1061-7 [8807115.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(8):829-34 [9134177.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2552-61 [9366570.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1101-34 [9454740.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):716-22 [10233762.001]
  • [Cites] Science. 1999 Jul 16;285(5426):412-5 [10411505.001]
  • [Cites] Nature. 1999 Aug 19;400(6746):776-80 [10466728.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1243-50 [15543150.001]
  • [Cites] Annu Rev Med. 2005;56:509-38 [15660525.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2227-34 [15522961.001]
  • [Cites] Immunity. 2005 Apr;22(4):439-50 [15845449.001]
  • [Cites] Immunity. 2005 May;22(5):643-54 [15894281.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):569-76 [15897263.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1251-60 [16109601.001]
  • [Cites] Immunity. 2005 Sep;23(3):331-42 [16169505.001]
  • [Cites] Immunity. 2005 Dec;23(6):611-20 [16356859.001]
  • [Cites] Annu Rev Med. 2003;54:29-52 [12359826.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):170-6 [12652467.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • (PMID = 17116734.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112100; United States / NHLBI NIH HHS / HL / R01 HL069438; United States / NCI NIH HHS / CA / R01-CA112100; United States / NHLBI NIH HHS / HL / R01-HL069438
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2118165
  •  go-up   go-down


11. Warnick E, Auger D: Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate. Clin J Oncol Nurs; 2009 Apr;13(2):177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
  • Primary central nervous system lymphoma (PCNSL) is a rare, extranodal form of non-Hodgkin lymphoma that most commonly presents with neurologic changes.
  • Comprehensive workup to diagnose PCNSL and rule out nodal non-Hodgkin lymphoma is critical to the development of an appropriate plan for therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] DNA-Binding Proteins / genetics. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349264.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Klemke CD, Goerdt S: Molecular biology and targeted therapy of cutaneous T-cell lymphomas. G Ital Dermatol Venereol; 2008 Dec;143(6):365-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous T-cell lymphoma (CTCL) is an extra-nodal non-Hodgkin lymphoma of mature T cells.
  • Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches.
  • This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. CD4-Positive T-Lymphocytes / immunology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169209.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CTAGE1 protein, human; 0 / Cytokines; 0 / Diphtheria Toxin; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins; 0 / Tetrahydronaphthalenes; 0 / zanolimumab; 25E79B5CTM / denileukin diftitox; 3A189DH42V / alemtuzumab; 58IFB293JI / vorinostat; A61RXM4375 / bexarotene
  • [Number-of-references] 95
  •  go-up   go-down


13. Oeffinger KC: Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):462-7; discussion 468
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential roles of different cancer therapies in the development of these risk factors are discussed.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064658.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100474-04; United States / NCI NIH HHS / CA / R01 CA100474; United States / NCI NIH HHS / CA / R01 CA100474-04; United States / NCI NIH HHS / CA / R01-CA-100474
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


14. Schindler C, Plumlee C: Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol; 2008 Aug;19(4):311-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inteferons pen the JAK-STAT pathway.
  • Characterization of how interferons (IFNs) mediate their biological response led to identification of the JAK-STAT signaling cascade, where JAKs are receptor-associated kinases and STATs the transcription factors they activate.
  • Today, 4 JAKs and 7 STATs are known to transduce pivotal signals for the over 50 members of the four-helix bundle family of cytokines.
  • This review will provide an overview and historical perspective of the JAK-STAT paradigm.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Apr 8;77(1):63-71 [7512451.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2182-91 [7514531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4776-80 [8197134.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4342-9 [8007943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6374-8 [8022790.001]
  • [Cites] Science. 1994 Sep 16;265(5179):1701-6 [8085155.001]
  • [Cites] Cell. 1995 Mar 10;80(5):729-38 [7889566.001]
  • [Cites] EMBO J. 1995 Mar 15;14(6):1166-75 [7720707.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1402-11 [7537213.001]
  • [Cites] Science. 1995 Nov 3;270(5237):794-7 [7481767.001]
  • [Cites] Science. 1995 Nov 3;270(5237):800-2 [7481769.001]
  • [Cites] Genomics. 1995 Sep 1;29(1):225-8 [8530075.001]
  • [Cites] Mol Cell Biol. 1996 Jan;16(1):288-93 [8524306.001]
  • [Cites] Immunity. 1995 Dec;3(6):771-82 [8777722.001]
  • [Cites] Nature. 1996 Apr 18;380(6575):627-30 [8602263.001]
  • [Cites] Nature. 1996 Apr 18;380(6575):630-3 [8602264.001]
  • [Cites] Cell. 1996 Feb 9;84(3):431-42 [8608597.001]
  • [Cites] Cell. 1996 Feb 9;84(3):443-50 [8608598.001]
  • [Cites] Immunity. 1996 Mar;4(3):313-9 [8624821.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):171-4 [8700208.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):174-7 [8700209.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7239-44 [9207075.001]
  • [Cites] Blood. 1998 May 15;91(10):3724-33 [9573009.001]
  • [Cites] EMBO J. 2000 Feb 1;19(3):392-9 [10654938.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2577-84 [10851056.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67 [13465720.001]
  • [Cites] Cell. 2004 Nov 24;119(5):587-9; discussion 589-590 [15550240.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Science. 2005 Jan 14;307(5707):269-73 [15653507.001]
  • [Cites] Immunity. 2005 Feb;22(2):247-57 [15723812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):3966-71 [15753310.001]
  • [Cites] Mol Cell. 2005 Mar 18;17(6):761-71 [15780933.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4524-9 [15764709.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21700-5 [15826948.001]
  • [Cites] Immunity. 2005 Jun;22(6):729-36 [15963787.001]
  • [Cites] Nat Rev Immunol. 2005 Jul;5(7):521-31 [15999093.001]
  • [Cites] Nat Rev Immunol. 2005 Sep;5(9):675-87 [16110316.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1131-3 [16082218.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40782-7 [16192273.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2638-44 [10851063.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39718-26 [10993888.001]
  • [Cites] Immunity. 2000 Oct;13(4):549-60 [11070173.001]
  • [Cites] Immunity. 2000 Oct;13(4):561-71 [11070174.001]
  • [Cites] Immunity. 2000 Dec;13(6):795-804 [11163195.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):349-54 [11201744.001]
  • [Cites] Biopolymers. 2000;55(4):254-87 [11169919.001]
  • [Cites] Genomics. 2001 Jan 15;71(2):150-5 [11161808.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1621-32 [11238899.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):517-28 [11463377.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):140-7 [11802163.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8004-11 [11773079.001]
  • [Cites] EMBO J. 2002 Apr 15;21(8):1978-86 [11953317.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S121-31 [11983158.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1143-8 [11994402.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):1-24 [12039028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8043-7 [12060750.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5662-8 [12138178.001]
  • [Cites] Immunity. 2002 Jul;17(1):63-72 [12150892.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6471-9 [12192045.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2623-9 [17312100.001]
  • [Cites] Science. 2007 Mar 2;315(5816):1274-8 [17332413.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1292-302 [17304212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2849-54 [17293456.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4901-7 [17404271.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):463-71 [17579067.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20059-63 [17502367.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1655-8 [17881746.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):919-22 [17943132.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1281-3 [18026076.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2903-11 [18292512.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):388-97 [18297515.001]
  • [Cites] Semin Immunol. 2007 Dec;19(6):400-8 [18166487.001]
  • [Cites] Trends Mol Med. 2008 Mar;14(3):109-19 [18261959.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):360-9 [18586112.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):341-50 [18621135.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):385-93 [18682296.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):414-22 [18708154.001]
  • [Cites] Semin Cell Dev Biol. 2008 Aug;19(4):319-28 [18721891.001]
  • [Cites] Development. 2006 Jul;133(13):2553-63 [16728475.001]
  • [Cites] Sci STKE. 2003 Aug 12;2003(195):RE13 [12915721.001]
  • [Cites] Genes Dev. 2003 Aug 15;17(16):1992-2005 [12923054.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34133-40 [12832402.001]
  • [Cites] Immunity. 2003 Dec;19(6):793-802 [14670297.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):407-19 [14673173.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):28-37 [14702106.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3563-72 [14597631.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12281-6 [12213961.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36052-60 [12138096.001]
  • [Cites] Nat Cell Biol. 2002 Oct;4(10):774-81 [12244326.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):63-8 [12469119.001]
  • [Cites] J Interferon Cytokine Res. 2005 Dec;25(12):745-8 [16375602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1000-5 [16418296.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):473-85 [16481475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7264-9 [16651533.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88 [16540365.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3237-44 [16857984.001]
  • [Cites] Immunity. 2006 Nov;25(5):745-55 [17088085.001]
  • [Cites] PLoS Genet. 2006 Aug 18;2(8):e131 [16934001.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3372-81 [17182865.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):41-51 [17186030.001]
  • [Cites] Immunity. 2007 Feb;26(2):163-76 [17306571.001]
  • [Cites] Annu Rev Immunol. 2004;22:503-29 [15032587.001]
  • [Cites] Nat Immunol. 2004 Apr;5(4):401-9 [15021879.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4661-6 [15070774.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):8037-47 [15340066.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):197-201 [15504906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8929-33 [3466167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6394-8 [3476954.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(22):8521-5 [2460869.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1988;53 Pt 2:799-802 [3254784.001]
  • [Cites] Genes Dev. 1989 Sep;3(9):1362-71 [2606351.001]
  • [Cites] Oncogene. 1990 Sep;5(9):1329-36 [2216457.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8555-9 [2236065.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):182-91 [1898761.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):2057-65 [1848670.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3315-24 [1630447.001]
  • [Cites] Cell. 1992 Jul 24;70(2):313-22 [1386289.001]
  • [Cites] Science. 1992 Aug 7;257(5071):809-13 [1496401.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7836-9 [1502203.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7840-3 [1502204.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1808-12 [1281555.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):69-77 [12483210.001]
  • [Cites] J Immunol. 2003 Jan 15;170(2):1077-83 [12517976.001]
  • [Cites] J Clin Invest. 2003 Feb;111(4):553-9 [12588893.001]
  • [Cites] Nat Immunol. 2003 May;4(5):471-7 [12679810.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4162-73 [12773560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4314-8 [8483949.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3245-54 [8497250.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):3951-63 [8321202.001]
  • [Cites] Cell. 1993 Jul 30;74(2):237-44 [8343952.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4221-8 [7693454.001]
  • [Cites] Nature. 1993 Nov 11;366(6451):129-35 [8232552.001]
  • [Cites] Nature. 1993 Nov 11;366(6451):166-70 [7901766.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1575-9 [7504325.001]
  • [Cites] Nature. 1993 Dec 9;366(6455):583-5 [7504785.001]
  • [Cites] Cell. 1994 Mar 11;76(5):821-8 [7510216.001]
  • [Cites] EMBO J. 1994 Mar 15;13(6):1350-6 [8137819.001]
  • [Cites] Cell. 1998 May 1;93(3):373-83 [9590172.001]
  • [Cites] Cell. 1998 May 1;93(3):385-95 [9590173.001]
  • [Cites] Cell. 1998 May 1;93(3):397-409 [9590174.001]
  • [Cites] Cell. 1998 May 29;93(5):827-39 [9630226.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):145-51 [9671298.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):33893-6 [9852037.001]
  • [Cites] Cell. 1999 Jan 8;96(1):121-30 [9989503.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):370-8 [10192386.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7138-46 [10490649.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4191-9 [10518610.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2604-16 [10521404.001]
  • (PMID = 18765289.001).
  • [ISSN] 1084-9521
  • [Journal-full-title] Seminars in cell & developmental biology
  • [ISO-abbreviation] Semin. Cell Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI050514-010001; United States / NHLBI NIH HHS / HL / R01 HL055413-05A1; United States / NIAID NIH HHS / AI / P01 AI050514; United States / NIAID NIH HHS / AI / P01 AI050514-010001; United States / NHLBI NIH HHS / HL / HL055413-05A1; United States / NIAID NIH HHS / AI / R01 AI058211-01A1; United States / NHLBI NIH HHS / HL / R01 HL055413; United States / NIAID NIH HHS / AI / AI058211-01A1; United States / NIAID NIH HHS / AI / R01 AI058211
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / STAT Transcription Factors; 9008-11-1 / Interferons; EC 2.7.10.2 / Janus Kinases
  • [Number-of-references] 158
  • [Other-IDs] NLM/ NIHMS77117; NLM/ PMC2741134
  •  go-up   go-down


15. Naz SM, Symmons DP: Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol; 2007 Oct;21(5):871-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether the development of RA initiates this process of premature ageing or is part of it is not clear.
  • Deaths due to lung cancer and non-Hodgkin's lymphoma, but not other cancers, are also increased.


16. Thai A, Prindiville T: Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis; 2010 Nov;4(5):511-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
  • OBJECTIVE: This article reviews the current literature and knowledge about hepatosplenic T-cell lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and immunophenotypic traits in relation to other lymphomas.
  • In addition, we explore the history of reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal relationship between infliximab use and HSTCL.
  • Keyword search phrases including "lymphoma," "hepatosplenic T-cell lymphoma," "Inflammatory bowel disease," "6-mercaptopurine," and "infliximab" were used in various combinations.
  • Only 22 cases of hepatosplenic T-cell lymphoma are associated with IBD treatment.
  • With bone marrow suppression, malignant degeneration may begin through selective uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible.
  • CONCLUSION: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome.
  • With the increasing number of reported cases of HSTCL linked to the use of infliximab, adalimumab, and AZA/6-MP, there appears to be an undeniable association of HSTCL development with the use of these agents.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hepatosplenic t-cell lymphoma .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21122554.001).
  • [ISSN] 1876-4479
  • [Journal-full-title] Journal of Crohn's & colitis
  • [ISO-abbreviation] J Crohns Colitis
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; E7WED276I5 / 6-Mercaptopurine; MRK240IY2L / Azathioprine
  •  go-up   go-down


17. Guo Z, Zhang T, Li X, Wang Q, Xu J, Yu H, Zhu J, Wang H, Wang C, Topol EJ, Wang Q, Rao S: Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics; 2005;6:58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Development of robust and efficient methods for analyzing and interpreting high dimension gene expression profiles continues to be a focus in computational biology.
  • Therefore, there is an open space for development of the timely and relevant computational algorithms that use robust functional expression profiles towards precise classification of complex human diseases at the modular level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12795-800 [12237400.001]
  • [Cites] Nucleic Acids Res. 2004;32(9):2685-94 [15148356.001]
  • [Cites] Genome Res. 2002 Nov;12(11):1703-15 [12421757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1128-33 [12538875.001]
  • [Cites] Genomics. 2003 Feb;81(2):98-104 [12620386.001]
  • [Cites] Bioinformatics. 2003 Mar 22;19(5):563-70 [12651713.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2914-23 [12515714.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1503-13 [12707033.001]
  • [Cites] Genome Res. 2003 May;13(5):965-79 [12695321.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1590-6 [12747878.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):226-30 [12754511.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):940-4 [12637343.001]
  • [Cites] Nature. 1999 Dec 2;402(6761 Suppl):C47-52 [10591225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Bioinformatics. 2000 Aug;16(8):707-26 [11099257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6730-5 [11381113.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):61-4 [11748456.001]
  • [Cites] Genomics. 2002 Jan;79(1):104-13 [11827463.001]
  • [Cites] Genomics. 2002 Feb;79(2):266-70 [11829497.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):549-54 [12002758.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):316-9 [12006977.001]
  • [Cites] Science. 2002 Aug 16;297(5584):1183-6 [12183631.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):991-7 [12355115.001]
  • [Cites] Urol Res. 2003 Jul;31(3):163-8 [12883880.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Nat Rev Genet. 2004 Feb;5(2):101-13 [14735121.001]
  • [Cites] Bioinformatics. 2004 Mar 1;20(4):578-80 [14990455.001]
  • [Cites] Genome Biol. 2004;5(3):R18 [15003121.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W492-9 [15215435.001]
  • [Cites] BMC Bioinformatics. 2004 Aug 26;5:116 [15333146.001]
  • [Cites] Genomics. 2005 Jan;85(1):16-23 [15607418.001]
  • [Cites] Sci China C Life Sci. 2004 Oct;47(5):396-405 [15623151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14031-6 [12388780.001]
  • (PMID = 15774002.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL066251
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1274255
  •  go-up   go-down


18. Slany RK: The molecular biology of mixed lineage leukemia. Haematologica; 2009 Jul;94(7):984-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of these novel enzymatic activities that are essentially involved in MLL fusion protein function presents potential new targets for a rational drug development.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24315-21 [15851483.001]
  • [Cites] Oncogene. 2005 Aug 18;24(35):5525-32 [15856011.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14765-70 [16199523.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9245-52 [16230385.001]
  • [Cites] Cell. 2005 Oct 21;123(2):207-18 [16239140.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1287-9 [16311605.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11367-74 [16357144.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):80-9 [16357944.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):586-600 [16510874.001]
  • [Cites] PLoS Genet. 2006 Apr;2(4):e51 [16604156.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):754-60 [16688745.001]
  • [Cites] Blood. 2006 Jul 1;108(1):297-304 [16507773.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Mol Cell. 2006 Aug 4;23(3):297-305 [16885020.001]
  • [Cites] Nat Struct Mol Biol. 2006 Aug;13(8):704-12 [16829959.001]
  • [Cites] Nat Struct Mol Biol. 2006 Aug;13(8):713-9 [16878130.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2397-409 [16951254.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8975-9 [16982737.001]
  • [Cites] EMBO J. 2006 Sep 20;25(18):4245-52 [16946699.001]
  • [Cites] EMBO J. 2006 Oct 4;25(19):4503-12 [16990798.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):438-49 [16965385.001]
  • [Cites] Hum Mol Genet. 2007 Jan 1;16(1):92-106 [17135274.001]
  • [Cites] Blood. 2007 May 1;109(9):4020-2 [17202314.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7275-83 [17671196.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):306-15 [17708529.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2774-5 [17881645.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1208-15 [17891136.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2258-63 [17690691.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2762-74 [17942707.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8466-79 [17923682.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4445-54 [17855633.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):633-42 [17875318.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2825-39 [18285465.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):338-45 [18371367.001]
  • [Cites] Mol Cell. 2008 Apr 11;30(1):7-10 [18406322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 27;105(21):7517-22 [18483194.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):36-46 [18598942.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6199-207 [18676843.001]
  • [Cites] Nature. 2008 Oct 30;455(7217):1205-9 [18806775.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):355-68 [18977325.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4690-3 [18796627.001]
  • [Cites] Genes Dev. 2008 Dec 15;22(24):3403-8 [19141473.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1109-16 [19155294.001]
  • [Cites] Mol Cell. 2009 Jan 30;33(2):181-91 [19187761.001]
  • [Cites] Cell Stem Cell. 2009 Feb 6;4(2):129-40 [19200802.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):815-23 [19060922.001]
  • [Cites] EMBO J. 2009 Apr 8;28(7):980-91 [19229293.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4011-5 [19144982.001]
  • [Cites] Leuk Res. 2009 Jul;33(7):937-47 [19232721.001]
  • [Cites] Blood. 2009 May 14;113(20):4922-9 [19029444.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1490-9 [19262598.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] Blood. 2001 Jul 1;98(1):201-9 [11418481.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8756-61 [11438682.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5678-87 [11463848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12902-7 [11687631.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):958-65 [11842107.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10753-5 [11805083.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3710-8 [12393701.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1107-17 [12453418.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1119-28 [12453419.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):186-94 [12482972.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2355-62 [12446457.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4230-46 [12773566.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8342-7 [12829790.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2395-402 [12805060.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cell. 2003 Oct 31;115(3):293-303 [14636557.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):617-28 [14701735.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5639-49 [15199122.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1364-72 [15269783.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Hum Genet. 1979 Jan 25;46(2):173-80 [283972.001]
  • [Cites] Hum Genet. 1979;53(1):5-16 [295044.001]
  • [Cites] Cancer Genet Cytogenet. 1982 Oct;7(2):165-72 [6959693.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1985 Nov;66(5):1115-23 [3931724.001]
  • [Cites] Blood. 1986 Mar;67(3):689-97 [3947743.001]
  • [Cites] Blood. 1986 Aug;68(2):597-9 [3730620.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):8136-40 [3141923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(6):2112-6 [2107543.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Mech Dev. 1991 Sep;35(2):113-27 [1684714.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Nat Genet. 1992 Oct;2(2):113-8 [1303259.001]
  • [Cites] Development. 1993 Jan;117(1):119-34 [7900984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10610-4 [7938000.001]
  • [Cites] Nature. 1995 Nov 30;378(6556):505-8 [7477409.001]
  • [Cites] Science. 1996 Mar 29;271(5257):1873-6 [8596958.001]
  • [Cites] Blood. 1997 Jul 15;90(2):535-41 [9226152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8732-7 [9238046.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4226-37 [9250666.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):122-9 [9418860.001]
  • [Cites] Oncogene. 1998 Mar 12;16(10):1351-6 [9546437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4152-7 [9539705.001]
  • [Cites] Blood. 1998 Jul 1;92(1):108-17 [9639506.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4663-71 [10467413.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1525-33 [10516753.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10470-8 [15542854.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3527-34 [15297313.001]
  • [Cites] Curr Biol. 2004 Nov 23;14(22):2063-9 [15556871.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 [15640349.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2124-31 [15528316.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8603-8 [15941828.001]
  • [Cites] Cell. 2005 Jun 17;121(6):873-85 [15960975.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1744-51 [10777208.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4655-64 [10970858.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1898-908 [11069025.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2249-58 [11259575.001]
  • (PMID = 19535349.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chromatin; 0 / MLL protein, human; 0 / Recombinant Fusion Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.7.- / RNA Polymerase II
  • [Number-of-references] 122
  • [Other-IDs] NLM/ PMC2704309
  •  go-up   go-down


19. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, Minarovits J: The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis; 2009;1(2):e2009012
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
  • These include lymphomas (Burkitt's lymphoma, Hodgkin's disease, T/NK-cell lymphoma, post-transplant lymphoproliferative disease, AIDS-associated lymphoma, X-linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, gastric carcinoma, carcinomas of major salivary glands, thymic carcinoma, mammary carcinoma) and a sarcoma (leiomyosarcoma).
  • In epithelial cells LMP1 can up-regulate DNA methyltransferases and, in Hodgkin lymphoma cells, induce the Polycomb group protein Bmi-1.
  • These interactions may result in epigenetic dysregulation and subsequent cellular dysfunctions that may manifest in or contribute to the development of pathological changes (e.g. initiation and progression of malignant neoplasms, autoimmune phenomena, immunodeficiency).
  • Elucidation of the epigenetic consequences of EBV-host interactions (within the framework of the emerging new field of patho-epigenetics) may have important implications for therapy and disease prevention, because epigenetic processes are reversible and continuous silencing of EBV genes contributing to patho-epigenetic changes may prevent disease development.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2287-91 [1594447.001]
  • [Cites] J Gen Virol. 1992 Jul;73 ( Pt 7):1687-92 [1321209.001]
  • [Cites] Virology. 1994 May 1;200(2):661-7 [8178450.001]
  • [Cites] J Virol. 1994 Sep;68(9):5375-83 [8057421.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6150-9 [7565767.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3129-36 [8874213.001]
  • [Cites] J Virol. 1997 Mar;71(3):1938-45 [9032325.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] J Mol Biol. 2005 Jul 22;350(4):631-40 [15967459.001]
  • [Cites] Am J Hematol. 2006 Jan;81(1):5-11 [16369970.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2995-3002 [16707594.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Bacteriol. 2006 Dec;188(23):8160-8 [16997949.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5722-35 [10891508.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Mar;75(6):2584-96 [11222681.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):469-76 [11669609.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):442-3 [17392803.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] J Virol. 2007 Dec;81(23):13242-7 [17898065.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] J Virol. 2002 May;76(10):4699-708 [11967287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4035-40 [12427740.001]
  • [Cites] J Virol. 2003 Apr;77(7):4261-72 [12634383.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1443-50 [12771413.001]
  • [Cites] J Virol. 2003 Jul;77(14):8166-72 [12829856.001]
  • [Cites] Virus Genes. 2003 Aug;27(1):57-66 [12913358.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19278-83 [17159145.001]
  • [Cites] J Gen Virol. 2008 Jun;89(Pt 6):1364-70 [18474551.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] J Virol. 2009 Apr;83(7):2930-40 [19129441.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Virol. 2009 Jul;83(14):7109-16 [19403674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):430-5 [10618435.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2343-9 [10713158.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):131-7 [11801549.001]
  • [Cites] Adv Cancer Res. 2003;89:133-56 [14587872.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Trends Microbiol. 2004 Nov;12(11):495-9 [15488390.001]
  • [Cites] J Virol. 2004 Nov;78(22):12308-19 [15507618.001]
  • [Cites] Science. 1980 Nov 7;210(4470):604-10 [6254144.001]
  • [Cites] J Virol. 1983 May;46(2):446-53 [6302313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] J Virol. 1998 Sep;72(9):7075-83 [9696800.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):46-56 [9858530.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Gene. 1999 Aug 5;236(1):87-95 [10433969.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] J Virol. 2004 Dec;78(24):14062-5 [15564516.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):542-52 [15706033.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):286-95 [15959556.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):344-53 [15959560.001]
  • [Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]
  • [Cites] Nature. 1986 May 15-21;321(6067):209-13 [2423876.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] Adv Cancer Res. 1988;50:95-158 [2837072.001]
  • [Cites] Cell. 1988 Jul 1;54(1):127-35 [2838178.001]
  • [Cites] Cell. 1988 Nov 4;55(3):427-33 [2846181.001]
  • [Cites] J Mol Biol. 1988 Oct 20;203(4):971-83 [3210246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(17):6498-502 [2549539.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):179-87 [1968655.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):285-97 [1968665.001]
  • [Cites] J Virol. 1990 Nov;64(11):5295-300 [2170673.001]
  • [Cites] EMBO J. 1991 Jan;10(1):143-51 [1846596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942-6 [1850841.001]
  • [Cites] J Virol. 1992 Jan;66(1):62-9 [1370095.001]
  • [Cites] J Gen Virol. 1991 Dec;72 ( Pt 12):3025-33 [1662694.001]
  • (PMID = 21416002.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033174
  •  go-up   go-down


20. Xu J, Sylvester R, Tighe AP, Chen S, Gudas LJ: Transcriptional activation of the suppressor of cytokine signaling-3 (SOCS-3) gene via STAT3 is increased in F9 REX1 (ZFP-42) knockout teratocarcinoma stem cells relative to wild-type cells. J Mol Biol; 2008 Mar 14;377(1):28-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional activation of the suppressor of cytokine signaling-3 (SOCS-3) gene via STAT3 is increased in F9 REX1 (ZFP-42) knockout teratocarcinoma stem cells relative to wild-type cells.
  • Rex1 (Zfp42), first identified as a gene that is transcriptionally repressed by retinoic acid (RA), encodes a zinc finger transcription factor expressed at high levels in F9 teratocarcinoma stem cells, embryonic stem cells, and other stem cells.
  • Loss of both alleles of Rex1 by homologous recombination alters the RA-induced differentiation of F9 cells, a model of pluripotent embryonic stem cells.
  • We identified Suppressor of Cytokine Signaling-3 (SOCS-3) as a gene that exhibits greatly increased transcriptional activation in RA, cAMP, and theophylline (RACT)-treated F9 Rex1(-/-) cells (approximately 25-fold) as compared to wild-type (WT) cells ( approximately 2.5-fold).
  • By promoter deletion, mutation, and transient transfection analyses, we have shown that this transcriptional increase is mediated by the STAT3 DNA-binding elements located between -99 to -60 in the SOCS-3 promoter.
  • Overexpression of STAT3 dominant-negative mutants greatly diminishes this SOCS-3 transcriptional increase in F9 Rex1(-/-) cells.
  • This increase in SOCS-3 transcription is associated with a four- to fivefold higher level of tyrosine-phosphorylated STAT3 in the RACT-treated F9 Rex1(-/-) cells as compared to WT.
  • Dominant-negative Src tyrosine kinase, Jak2, and protein kinase A partially reduce the transcriptional activation of the SOCS 3 gene in RACT-treated F9 Rex1 null cells.
  • In contrast, parathyroid hormone peptide enhances the effect of RA in F9 Rex1(-/-) cells, but not in F9 WT.
  • Thus, Rex1, which is highly expressed in stem cells, inhibits signaling via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, thereby modulating the differentiation of F9 cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • Hazardous Substances Data Bank. 2-MERCAPTOETHANOL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Apr 15;99(8):2637-46 [11929748.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S121-31 [11983158.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1143-8 [11994402.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Genome Biol. 2003;4(2):206 [12620113.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1325-35 [12628925.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):546-50 [12754506.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):121-6 [12829247.001]
  • [Cites] Ital J Biochem. 2003 Mar;52(1):28-32 [12833635.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):524-32 [12888825.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9342-7 [12867595.001]
  • [Cites] J Cell Physiol. 2003 Nov;197(2):157-68 [14502555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11854-60 [12925733.001]
  • [Cites] Biochem J. 2003 Nov 1;375(Pt 3):517-29 [12940771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14926-31 [14634211.001]
  • [Cites] Nat Med. 2004 Jan;10(1):55-63 [14702635.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2023-9 [14959844.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16349-55 [14764607.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5434-46 [15169905.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3934-9 [15173005.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):720-8 [15343391.001]
  • [Cites] Cell. 1977 Mar;10(3):381-91 [191196.001]
  • [Cites] Cell. 1980 Sep;21(2):347-55 [6250719.001]
  • [Cites] Nature. 1981 May 21;291(5812):235-7 [6164928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Oct;80(19):5880-4 [6310600.001]
  • [Cites] Dev Biol. 1985 Jan;107(1):75-86 [2981185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(22):7881-5 [2825168.001]
  • [Cites] Mol Cell Biol. 1988 Sep;8(9):3906-17 [2906112.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16672-8 [2550452.001]
  • [Cites] Mol Cell Biol. 1989 Dec;9(12):5623-9 [2511439.001]
  • [Cites] Am J Respir Cell Mol Biol. 1990 Apr;2(4):319-20 [2157472.001]
  • [Cites] Int J Dev Biol. 1989 Mar;33(1):105-15 [2485690.001]
  • [Cites] Development. 1991 Nov;113(3):815-24 [1821852.001]
  • [Cites] Mol Endocrinol. 1993 Apr;7(4):543-50 [8388997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9601-5 [8105479.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1313-8 [7505394.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Leukemia. 2006 May;20(5):857-69 [16498386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9099-103 [2556699.001]
  • [Cites] Cell. 1994 Apr 8;77(1):63-71 [7512451.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15399-402 [7910825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4215-8 [7538664.001]
  • [Cites] Annu Rev Biochem. 1995;64:201-33 [7574480.001]
  • [Cites] Cell. 1996 Feb 9;84(3):331-4 [8608586.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3963-6 [8632998.001]
  • [Cites] Endocrinology. 1996 Sep;137(9):3999-4009 [8756577.001]
  • [Cites] Cell Growth Differ. 1996 Oct;7(10):1393-401 [8891343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Immunity. 1997 Jul;7(1):1-11 [9252115.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] EMBO J. 1997 Nov 3;16(21):6452-65 [9351827.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1866-78 [9528758.001]
  • [Cites] Genes Dev. 1998 Jul 1;12(13):2048-60 [9649508.001]
  • [Cites] J Biomed Sci. 1998;5(2):79-85 [9662066.001]
  • [Cites] Annu Rev Biochem. 1998;67:227-64 [9759489.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1385-92 [9769331.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Oct;30(10):1081-5 [9785473.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):C1640-52 [9843726.001]
  • [Cites] EMBO J. 1999 Jan 15;18(2):375-85 [9889194.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17209-18 [10358079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6964-9 [10359822.001]
  • [Cites] Life Sci. 1999;64(24):2173-86 [10374907.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5552-60 [16007214.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6699-708 [16007169.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:451-80 [16402912.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):499-507 [16344273.001]
  • [Cites] Expert Opin Biol Ther. 2006 Mar;6(3):231-41 [16503733.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):604-14 [16123385.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23319-25 [16714766.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33172-81 [16956893.001]
  • [Cites] Oncogene. 2006 Nov 16;25(54):7138-47 [16732315.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):35812-25 [17008315.001]
  • [Cites] Mol Carcinog. 2006 Dec;45(12):887-900 [16865673.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6212-20 [17616678.001]
  • [Cites] Differentiation. 2007 Nov;75(9):853-70 [17634071.001]
  • [Cites] Exp Hematol. 2002 Aug;30(8):896-904 [12160841.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Mol Cell Endocrinol. 2002 Sep 30;195(1-2):119-33 [12354678.001]
  • [Cites] Science. 2002 Oct 18;298(5593):597-600 [12228720.001]
  • [Cites] Trends Cell Biol. 2002 Nov;12(11):502-8 [12446111.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):372-84 [12554639.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1316-33 [12556491.001]
  • [Cites] EMBO J. 1999 Aug 2;18(15):4261-9 [10428964.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Cell Mol Life Sci. 1999 Sep;55(12):1568-77 [10526574.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1569-75 [15684405.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):970-9 [15592503.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10749-58 [15653674.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3397-408 [15735721.001]
  • [Cites] J Clin Invest. 1999 Nov;104(9):1277-85 [10545526.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15099-105 [10747872.001]
  • [Cites] Oncogene. 2000 Apr 20;19(17):2075-85 [10815799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6493-8 [10829066.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2813-9 [10910765.001]
  • [Cites] Trends Biochem Sci. 2000 Oct;25(10):496-502 [11050435.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1056-62 [11159537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7319-24 [11404481.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9324-9 [11481489.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1880-90 [11682619.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1735-40 [11748254.001]
  • (PMID = 18237746.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA043796-16; United States / NCI NIH HHS / CA / CA043796-15; United States / NCI NIH HHS / CA / CA043796-18; United States / NCI NIH HHS / CA / CA043796-16; United States / NCI NIH HHS / CA / CA043796-17; United States / NCI NIH HHS / CA / R01 CA043796-17; United States / NCI NIH HHS / CA / R01 CA043796-18; United States / NCI NIH HHS / CA / R01 CA043796-14; United States / NCI NIH HHS / CA / CA043796-14; United States / NCI NIH HHS / CA / R01 CA043796; United States / NCI NIH HHS / CA / R01 CA043796-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Peptides; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Rex-1 protein, mouse; 0 / STAT3 Transcription Factor; 0 / Socs3 protein, mouse; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Transcription Factors; 5688UTC01R / Tretinoin; 60-24-2 / Mercaptoethanol; 63X7MBT2LQ / Bucladesine; C137DTR5RG / Theophylline; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  • [Other-IDs] NLM/ NIHMS242643; NLM/ PMC2972193
  •  go-up   go-down


21. Al-Ejeh F, Darby JM, Tsopelas C, Smyth D, Manavis J, Brown MP: APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy. PLoS One; 2009;4(2):e4558
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY/PRINCIPAL FINDINGS: Brisk tumor cell apoptosis is induced in the syngeneic EL4 lymphoma model after treatment of tumor-bearing mice with DNA-damaging cyclophosphamide/etoposide chemotherapy.
  • We believe that the ability of radiolabeled DAB4 to rapidly assess the apoptotic tumor response and, consequently, to potentially predict extended survival justifies its future clinical development as a radioimmunoscintigraphic agent.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):580-98 [16670384.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1041-53 [9777936.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):1059-66 [16741317.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:11-5 [16783564.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3261-73 [16829650.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3282-92 [16829652.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5659-67 [17020967.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3198-206 [17545523.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2534-9 [17577031.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5509s-5518s [17875783.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5519s-5527s [17875784.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Nov 3;275(44):34465-70 [10913436.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):21-7 [14687785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1125-35 [10421547.001]
  • [Cites] Biol Cell. 2004 Oct;96(8):603-15 [15519695.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] FEBS J. 2005 May;272(9):2118-31 [15853797.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7967-85 [16299226.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3934-42 [16320341.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(4):1445-51 [16449655.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1255-60 [16452175.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Jan;5(1):44-54 [18097456.001]
  • [Cites] Immunol Rev. 2008 Apr;222:328-40 [18364012.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Nucl Med Biol. 2009 May;36(4):395-402 [19423007.001]
  • [Cites] Development. 2000 Dec;127(24):5245-52 [11076747.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2145-52 [11147583.001]
  • [Cites] N Engl J Med. 2001 Apr 12;344(15):1140-4 [11297706.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1241-4 [11689890.001]
  • [Cites] Arthritis Rheum. 2002 Jan;46(1):202-8 [11817591.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Cancer J. 2002 Mar-Apr;8(2):82-92 [11999952.001]
  • [Cites] Annu Rev Biochem. 2002;71:375-403 [12045101.001]
  • [Cites] Cell Mol Life Sci. 2002 Aug;59(8):1358-65 [12363038.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):955-60 [12631592.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3483-7 [12972524.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):169-74 [14722606.001]
  • [Cites] Technol Cancer Res Treat. 2004 Feb;3(1):23-32 [14750890.001]
  • [Cites] Nat Struct Mol Biol. 2004 Apr;11(4):303-5 [15048103.001]
  • [Cites] Mass Spectrom Rev. 2004 Sep-Oct;23(5):333-49 [15264233.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Exp Cell Res. 1989 Nov;185(1):73-85 [2530103.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3825-34 [7641200.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6349-54 [9600968.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):901-3 [16741296.001]
  • (PMID = 19247492.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / apomab; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2645692
  •  go-up   go-down


22. Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L: T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology; 2009 Dec 17;6:116
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic inflammation has long been associated with a wide range of malignancies, is now widely accepted as a risk factor for development of cancer, and has been implicated as a promoter of a variety of cancers including hematopoietic malignancies.
  • We have described a mouse model uniquely suited to examine the link between inflammation and lymphoma in which the Tax oncogene, expressed in activated T and NK cells, perpetuates chronic inflammation that begins as microscopic intraepithelial lesions and develops into inflammatory nodules, subcutaneous tumors, and large granular lymphocytic leukemia.
  • In experiments in which long-term effects of inflammation on disease outcome were monitored, the development of lymphoma was promoted by an inflammatory stimulus.
  • Finally we demonstrated that activation of T-cells in T-cell receptor (TCR) transgenic TAX-LUC animals dramatically exacerbated the development of subcutaneous TCR- CD16+ LGL tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] J Leukoc Biol. 2001 Dec;70(6):849-60 [11739546.001]
  • [Cites] Biochim Biophys Acta. 2002 Feb 13;1589(1):1-13 [11909637.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Nature. 1990 Aug 23;346(6286):756-60 [2167455.001]
  • [Cites] J Biol Chem. 1991 Dec 25;266(36):24433-8 [1761544.001]
  • [Cites] Skin Pharmacol. 1991;4(4):262-71 [1789987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6065-9 [1385868.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):196-203 [1634608.001]
  • [Cites] Agents Actions. 1992 Nov;37(3-4):260-7 [1338267.001]
  • [Cites] Hepatology. 1995 Jan;21(1):190-8 [7806154.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):713-21 [7836924.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S162-9 [8797719.001]
  • [Cites] Blood. 1997 Jul 15;90(2):783-94 [9226179.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3305-11 [15292059.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35713-22 [16105841.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Feb;2(2):90-7; quiz 1 p following 113 [16264881.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4294-302 [16118323.001]
  • [Cites] Cell. 2006 Feb 24;124(4):823-35 [16497591.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9220-5 [16751281.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6731-48 [17072325.001]
  • [Cites] Front Biosci. 2008;13:170-7 [17981535.001]
  • [Cites] Autoimmunity. 2008 Mar;41(2):154-62 [18324485.001]
  • [Cites] Immunol Rev. 2008 Apr;222:162-79 [18364001.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38 [18628784.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 [18832156.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1493-500 [18971418.001]
  • [Cites] Nat Med. 2009 Apr;15(4):455-61 [19305414.001]
  • [Cites] Immunity. 2006 Nov;25(5):701-15 [17098202.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1200-8 [11493471.001]
  • (PMID = 20017942.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-07; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10073; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / CA94056; United States / NCI NIH HHS / CA / CA100730-07; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B; 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2806367
  •  go-up   go-down


23. Huysentruyt LC, McGrath MS: The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol; 2010 Apr;87(4):627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.
  • The primary difference between lymphoma in non-HIV-infected individuals and those with ARL is that ARL is consistently high-grade and metastatic.
  • This review will highlight and discuss the role of macrophage viral reservoirs in the development and progression of ARLs and hopefully, shed light on this new and interesting field.


24. Zhang B, Zhang Y, Dagher MC, Shacter E: Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res; 2005 Jul 15;65(14):6054-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RhoGDI is frequently overexpressed in human tumors and chemo-resistant cancer cell lines, raising the possibility that RhoGDI might play a role in the development of drug resistance in cancer cells.
  • We found that overexpression of RhoGDI increased resistance of cancer cells (MDA-MB-231 human breast cancer cells and JLP-119 lymphoma cells) to the induction of apoptosis by two chemotherapeutic agents: etoposide and doxorubicin.
  • [MeSH-major] Apoptosis / physiology. Breast Neoplasms / pathology. Doxorubicin / antagonists & inhibitors. Etoposide / antagonists & inhibitors. Guanine Nucleotide Dissociation Inhibitors / physiology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024605.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARHGDIA protein, human; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Caspase Inhibitors; 0 / Guanine Nucleotide Dissociation Inhibitors; 0 / RNA, Small Interfering; 0 / rho Guanine Nucleotide Dissociation Inhibitor alpha; 0 / rho-Specific Guanine Nucleotide Dissociation Inhibitors; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


25. Tabuchi Y, Takasaki I, Zhao QL, Wada S, Hori T, Feril LB Jr, Tachibana K, Nomura T, Kondo T: Genetic networks responsive to low-intensity pulsed ultrasound in human lymphoma U937 cells. Cancer Lett; 2008 Nov 8;270(2):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic networks responsive to low-intensity pulsed ultrasound in human lymphoma U937 cells.
  • To clarify the detailed molecular mechanism underlying cellular responses to nonthermal low-intensity pulsed ultrasound (LIPUS), gene expression patterns and genetic networks in human lymphoma U937 cells were examined using global-scale microarrays and computational gene expression analysis tools.
  • For down-regulated genes, the significant genetic network D was associated with cellular growth and proliferation, gene expression, or cellular development.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Regulatory Networks. Lymphoma / genetics. Sonication

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571840.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


26. Baum KJ, Ren R: Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol; 2008 Jun 05;1:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most BCR/ABL + N17 H-Ras mice eventually developed pro-B lymphoblastic leukemia/lymphoma (B-ALL).
  • These results suggest that Ras activation is essential for the development of lymphoid and erythroid cells but not myeloid cells and that Ras is a critical target of BCR/ABL in the pathogenesis of CML, but not B-ALL.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 [12728271.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3938-46 [12907435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] J Exp Med. 1976 Jun 1;143(6):1453-63 [178822.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Cell. 1993 Oct 8;75(1):175-85 [8402896.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):764-73 [8112292.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:327-30 [8024205.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):307-13 [7807010.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):276-85 [7835338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1709-13 [7878045.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1151-9 [9294608.001]
  • [Cites] Genes Dev. 1997 Oct 1;11(19):2468-81 [9334313.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7019-31 [9384581.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6918-28 [10490629.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):20-8 [10805516.001]
  • [Cites] Blood. 2000 Jul 15;96(2):664-70 [10887132.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):693-704 [11030348.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):840-53 [11154271.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1444-52 [11238881.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1603-8 [11309191.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8236-48 [11781838.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2957-68 [11929787.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):479-92 [12124177.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):165-70 [12527752.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):6-13 [12573429.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4572-81 [12458225.001]
  • [Cites] Cancer Treat Res. 2003;115:189-208 [12613198.001]
  • (PMID = 18577264.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068008; United States / NCI NIH HHS / CA / CA68008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2438443
  •  go-up   go-down


27. Gustafsson B, Bogdanovic G: Specific viruses were not detected in Guthrie cards from children who later developed leukemia. Pediatr Hematol Oncol; 2007 Dec;24(8):607-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are hypotheses concerning infectious mechanism in the development of acute lymphoblastic leukemia (ALL).
  • The results do not support that these viruses have contributed to the development of a substantial part of the ALL cases in Swedish children.
  • [MeSH-major] DNA Tumor Viruses. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092251.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M: Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A; 2005 Sep 13;102(37):13266-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Likewise, acute lymphoblastic leukemia cells are typically arrested at early stages of B cell development.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Protein-Tyrosine Kinases / deficiency

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2003 Dec 1;171(11):5988-96 [14634110.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1011-8 [12854903.001]
  • [Cites] J Exp Med. 2004 Mar 1;199(5):673-85 [14993251.001]
  • [Cites] Genes Dev. 1993 Dec;7(12B):2520-32 [8276236.001]
  • [Cites] Nat Med. 1996 Aug;2(8):876-82 [8705856.001]
  • [Cites] Science. 1996 Aug 23;273(5278):1096-100 [8688094.001]
  • [Cites] Hum Gene Ther. 1997 Dec 10;8(18):2193-206 [9449373.001]
  • [Cites] Pediatrics. 1998 Feb;101(2):276-84 [9445504.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] J Virol. 1999 Apr;73(4):2613-21 [10074106.001]
  • [Cites] J Virol. 1999 May;73(5):4083-9 [10196304.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):367-75 [15611260.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1837-52 [15939795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10014-9 [12119411.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1291-305 [12438421.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):31-7 [12469118.001]
  • [Cites] Nature. 2003 May 22;423(6938):452-6 [12761551.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6747-52 [12738882.001]
  • [Cites] J Exp Med. 2003 Jul 7;198(1):91-8 [12835482.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • (PMID = 16141323.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AM051275/ AM051276/ AM051277/ AM051278/ AM051279/ AM051280/ AM051281/ AM051282/ AM051283/ AM051284/ AM051285/ AM051286
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1201599
  •  go-up   go-down


29. Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL: Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. J Immunother; 2007 Jan;30(1):64-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
  • Rituximab is an anti-CD20 monoclonal antibody that activates ADCC in non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Interleukin-2 / pharmacology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198084.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunoglobulin Fc Fragments; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


30. Maluf-Filho F, Dotti CM, Farias AQ, Kupski C, Chaves DM, Artifon E, Nakao F, Rossini GF, Paulo GA, Ardengh JC, Silva JE, Rossini L, Lima LF, Averbach M, Cury MS, D'Aassunção MA, Silva MC, Ney MV, Spinosa S, Matuguma SE, Guaraldi S, Arantes V, Mello VH: [I Brazilian consensus of endoscopic ultrasonography]. Arq Gastroenterol; 2007 Oct-Dec;44(4):353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consensus was reached for several clinical scenarios for which the impact of endoscopic ultrasonography findings were supported by level 1 evidences: differential diagnosis of subepithelial lesions and thickening of gastric folds, staging and diagnosis of unresectable esophageal cancer, indirect signs of peritoneal involvement of gastric cancer, MALT gastric lymphoma and rectal cancer staging, diagnosis of common bile duct and gallbladder stones, diagnosis of chronic pancreatitis and differential diagnosis of a solid mass in chronic pancreatitis, differential diagnosis of the pancreatic cyst, prediction of the results of the endoscopic treatment of esophageal varices and diagnosis and staging of non-small cell lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317657.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Number-of-references] 53
  •  go-up   go-down


31. Berdis AJ: DNA polymerases as therapeutic targets. Biochemistry; 2008 Aug 12;47(32):8253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of nucleoside and non-nucleoside inhibitors as antiviral agents is discussed with particular emphasis on their mechanism of action, structure-activity relationships, toxicity, and mechanism of resistance.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1992 Nov 17;31(45):10984-94 [1332748.001]
  • [Cites] J Mol Biol. 1992 Oct 20;227(4):981-4 [1433302.001]
  • [Cites] Annu Rev Biochem. 1993;62:685-713 [7688945.001]
  • [Cites] Science. 1995 Feb 17;267(5200):988-93 [7532321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760-4 [7535930.001]
  • [Cites] Leukemia. 1995 Oct;9 Suppl 1:S75-85 [7475321.001]
  • [Cites] Biochemistry. 1997 Nov 18;36(46):14064-70 [9369478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702 [9671741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13471-6 [9811824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7 [9990051.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17395-8 [10364165.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Viral Immunol. 2004;17(4):535-44 [15671750.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72 [16101488.001]
  • [Cites] Biochemistry. 2005 Oct 4;44(39):13111-21 [16185079.001]
  • [Cites] Biochemistry. 2006 Jun 13;45(23):7334-40 [16752922.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52 [17023173.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Drugs. 2007;67(11):1633-55 [17661532.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Sep;4(5):513-31 [17880274.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1035-9 [17979806.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):204-17 [18231906.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):539-66 [18319069.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2035-42 [18391035.001]
  • [Cites] Biochemistry. 2008 Aug 19;47(33):8527-37 [18652487.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):F1-7 [10708276.001]
  • [Cites] Antimicrob Agents Chemother. 2000 May;44(5):1186-94 [10770750.001]
  • [Cites] J Mol Biol. 2000 Jul 7;300(2):403-18 [10873473.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1375-9 [11100123.001]
  • [Cites] J Virol. 2001 May;75(10):4832-42 [11312355.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23616-23 [11319228.001]
  • [Cites] Antivir Ther. 2001 Jun;6(2):115-26 [11491416.001]
  • [Cites] Acc Chem Res. 2001 Dec;34(12):938-45 [11747411.001]
  • [Cites] Biochemistry. 2002 Aug 27;41(34):10571-6 [12186540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5 [12386343.001]
  • [Cites] DNA Repair (Amst). 2002 Feb 28;1(2):125-35 [12509259.001]
  • [Cites] J Virol. 2003 Jun;77(11):6127-37 [12743270.001]
  • [Cites] J Am Chem Soc. 2003 May 21;125(20):6016-7 [12785806.001]
  • [Cites] Curr Pharm Des. 2003;9(31):2593-613 [14529544.001]
  • [Cites] Biochemistry. 2003 Dec 23;42(50):14711-9 [14674745.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6221-4 [14722107.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):469-74 [15107837.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S2-S12 [15319664.001]
  • [Cites] Curr Opin Pharmacol. 2004 Oct;4(5):453-64 [15351349.001]
  • [Cites] New Microbiol. 2004 Jul;27(3):207-14 [15460522.001]
  • [Cites] Can J Neurol Sci. 1977 May;4(2):81-8 [322829.001]
  • [Cites] J Biol Chem. 1989 May 5;264(13):7405-11 [2540193.001]
  • [Cites] J Biol Chem. 1990 Sep 25;265(27):16617-25 [1697861.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):3-17 [1699280.001]
  • [Cites] Ann N Y Acad Sci. 1990;616:328-43 [2078027.001]
  • [Cites] Mol Pharmacol. 1992 Jan;41(1):64-8 [1732724.001]
  • [Cites] Am J Med. 1992 Feb 14;92(2A):3S-7S [1371038.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2326-33 [8387546.001]
  • (PMID = 18642851.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118408; United States / NCI NIH HHS / CA / R01 CA118408-04; United States / NCI NIH HHS / CA / CA118408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Reverse Transcriptase Inhibitors; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  • [Number-of-references] 55
  • [Other-IDs] NLM/ NIHMS112579; NLM/ PMC2692436
  •  go-up   go-down


32. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet; 2008 Mar 22;371(9617):1030-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while reducing the toxic side-effects of current intensive regimens.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358930.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA68484; United States / NINR NIH HHS / NR / NR07610; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / CA90246; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NCI NIH HHS / CA / CA52259; United States / NCI NIH HHS / CA / CA60419; United States / NIGMS NIH HHS / GM / GM61393; United States / NCI NIH HHS / CA / CA06516; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / P30 CA006516
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 171
  •  go-up   go-down


33. Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R: The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood; 2010 Apr 29;115(17):3570-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transplantation of MLL.AF4- or mock-transduced LSPCs did not result in disease development during an observation period of 13 months.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Leukemic. Myeloid-Lymphoid Leukemia Protein / metabolism. Nuclear Proteins / metabolism. Oncogene Proteins, Fusion / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194896.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aff1 protein, mouse; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Mll protein, mouse
  •  go-up   go-down


34. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut; 2007 Jun;56(6):772-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma;.
  • Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Child. Drug Resistance, Bacterial. Dyspepsia / microbiology. Gastroesophageal Reflux / microbiology. Humans. Lymphoma, B-Cell, Marginal Zone / microbiology. Stomach Neoplasms / microbiology. Stomach Neoplasms / prevention & control


35. Svojgr K, Burjanivova T, Vaskova M, Kalina T, Stary J, Trka J, Zuna J: Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia. Immunol Lett; 2009 Feb 21;122(2):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During normal lymphocyte development, some adaptors show significant dynamics (gradual decrease of NTAL and increase of LAT and LIME during the T-cell maturation, decrease of PAG in B-precursors, high levels of LIME in peripheral B-lymphocytes).
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. B-Lymphocytes / metabolism. Lymphopoiesis / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183565.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adaptor Proteins, Vesicular Transport; 0 / Biomarkers, Tumor; 0 / LAT protein, human; 0 / LAT2 protein, human; 0 / Lck-interacting protein, human; 0 / Membrane Proteins; 0 / PAG1 protein, human
  •  go-up   go-down


36. Lungu G, Kuang X, Stoica G, Wong PK: Monosodium luminol upregulates the expression of Bcl-2 and VEGF in retrovirus-infected mice through downregulation of corresponding miRNAs. Acta Virol; 2010;54(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous studies showed that the antioxidant drug monosodium luminol (GVT) prevented the development of ND in ts1-infected mice.
  • In this study, we analyzed effect of GVT on the expression of B-cell lymphoma-2 protein (Bcl-2) and vascular endothelial growth factor (VEGF) in central nervous system (CNS) tissues of these animals.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201611.001).
  • [ISSN] 0001-723X
  • [Journal-full-title] Acta virologica
  • [ISO-abbreviation] Acta Virol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 2R01 NS043984 05 A1; United States / NIMH NIH HHS / MH / 5R01 MH071583 18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vascular Endothelial Growth Factor A; 114100-40-2 / Bcl2 protein, mouse; 5EXP385Q4F / Luminol
  •  go-up   go-down


37. Schubert R, Schmitz N, Pietzner J, Tandi C, Theisen A, Dresel R, Christmann M, Zielen S: Growth hormone supplementation increased latency to tumourigenesis in Atm-deficient mice. Growth Factors; 2009 Oct;27(5):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Growth hormone (GH) is important for cell growth and differentiation, has multiple effects on lymphoid tissue and may promote blast cell proliferation and cancer development.
  • Thus, our data demonstrated that GH treatment is not necessarily accompanied by increased cancer development in diseases with chromosomal instability and cancer susceptibility and might be beneficial for AT patients.
  • [MeSH-minor] Animals. Ataxia Telangiectasia Mutated Proteins. Disease Models, Animal. Female. Humans. Lymphoma / etiology. Lymphoma / genetics. Lymphoma / physiopathology. Lymphoma / prevention & control. Male. Mice. Rats. T-Lymphocytes / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19626507.001).
  • [ISSN] 1029-2292
  • [Journal-full-title] Growth factors (Chur, Switzerland)
  • [ISO-abbreviation] Growth Factors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Recombinant Proteins; 0 / Tumor Suppressor Proteins; 9002-72-6 / Growth Hormone; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


38. Savage SA, Alter BP: The role of telomere biology in bone marrow failure and other disorders. Mech Ageing Dev; 2008 Jan-Feb;129(1-2):35-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of telomere biology in bone marrow failure and other disorders.
  • Telomeres, consisting of nucleotide repeats and a protein complex at chromosome ends, are essential in maintaining chromosomal integrity.
  • Dyskeratosis congenita (DC) is the inherited bone marrow failure syndrome (IBMFS) that epitomizes the effects of abnormal telomere biology.
  • Patients with DC have extremely short telomere lengths (<1st percentile) and many have mutations in telomere biology genes.
  • Interpretation of telomere length in other IBMFSs is less straightforward.
  • Abnormal telomere shortening has been reported in patients with apparently acquired hematologic disorders, including aplastic anemia, myeolodysplasia, paroxysmal nocturnal hemoglobinuria, and leukemia.
  • In these disorders, the shortest-lived cells have the shortest telomeres, suggestive of increased hematopoietic stress.
  • Telomeres are also markers of replicative and/or oxidative stress in other complex disease pathways, such as inflammation, stress, and carcinogenesis.
  • The spectrum of related disorders caused by mutations in telomere biology genes extends beyond classical DC to include marrow failure that does not respond to immunosuppression, idiopathic pulmonary fibrosis, and possibly other syndromes.
  • We suggest that such patients be categorized as having an inherited disorder of telomere biology.
  • Longitudinal studies of patients with very short telomeres but without classical DC are necessary to further understand the long-term sequelae, such as malignancy, osteonecrosis/osteoporosis, and pulmonary and liver disease.
  • [MeSH-major] Anemia, Aplastic / genetics. Telomere / metabolism
  • [MeSH-minor] Dyskeratosis Congenita / genetics. Hematologic Diseases / genetics. Humans. Inheritance Patterns. Mutation. Syndrome

  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Jun;105(4):883-93 [10554797.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):997-1001 [10554813.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):551-5 [10591218.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1883-90 [10706851.001]
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(4):441-7 [10723589.001]
  • [Cites] Blood. 2001 Jan 15;97(2):575-7 [11154240.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):39-44 [11196268.001]
  • [Cites] Blood. 2001 Feb 15;97(4):895-900 [11159514.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):677-85 [11257099.001]
  • [Cites] Blood Cells Mol Dis. 2001 Mar-Apr;27(2):353-7 [11259155.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):1025-30 [11298602.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:1-7; discussion 7-8 [11458496.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:293-303; discussion 303-4 [11458518.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):203-6 [11528113.001]
  • [Cites] Bone Marrow Transplant. 2001 Jun;27(12):1283-6 [11548846.001]
  • [Cites] FEBS Lett. 2001 Sep 28;506(1):22-6 [11591364.001]
  • [Cites] Exp Gerontol. 2002 Apr;37(4):523-31 [11830355.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):491-6 [11841457.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):564-79 [11850781.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] Hum Mol Genet. 2002 Feb 15;11(4):439-44 [11854176.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):249-55 [8272086.001]
  • [Cites] EMBO J. 1994 Jan 1;13(1):110-7 [8306954.001]
  • [Cites] Am J Med Genet. 1994 Feb 15;49(4):374-7 [8160728.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3557-60 [8012981.001]
  • [Cites] Am J Hum Genet. 1994 Nov;55(5):876-82 [7977349.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(4):389-92 [9051251.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1552-60 [9118038.001]
  • [Cites] Eur J Hum Genet. 1997 May-Jun;5(3):137-48 [9272737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13782-5 [9391104.001]
  • [Cites] Leukemia. 1998 Jan;12(1):13-24 [9436916.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):178-81 [9449873.001]
  • [Cites] Cell. 1998 Mar 6;92(5):587-90 [9506510.001]
  • [Cites] Blood. 1998 May 15;91(10):3582-92 [9572992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5607-10 [9576930.001]
  • [Cites] Nat Genet. 1998 May;19(1):32-8 [9590285.001]
  • [Cites] Nat Biotechnol. 1998 Aug;16(8):743-7 [9702772.001]
  • [Cites] Immunity. 1998 Aug;9(2):151-7 [9729035.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):169-75 [9988267.001]
  • [Cites] Blood. 1999 May 1;93(9):2824-30 [10216076.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1155-60 [10353751.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3588-90 [15284109.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):285-96 [15557801.001]
  • [Cites] Am J Hum Genet. 2005 Jan;76(1):147-51 [15520935.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3927-35 [15319283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17312-5 [15574496.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):393-9 [15621829.001]
  • [Cites] Annu Rev Med. 2005;56:1-16 [15660498.001]
  • [Cites] Leukemia. 2005 Feb;19(2):296-8 [15549144.001]
  • [Cites] Haematologica. 2005 Mar;90(3):307-16 [15749662.001]
  • [Cites] N Engl J Med. 2005 Apr 7;352(14):1413-24 [15814878.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2509-19 [16778145.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:24-8, 516 [17124035.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:63-71 [17124042.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:72-7 [17124043.001]
  • [Cites] Am J Epidemiol. 2007 Jan 1;165(1):14-21 [17043079.001]
  • [Cites] Am J Hum Genet. 2006 Dec;79(6):1110-8 [17186470.001]
  • [Cites] Lancet. 2007 Jan 13;369(9556):107-14 [17223473.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Mar;13(3):366-8 [17317590.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):673-81 [17379077.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1317-26 [17392301.001]
  • [Cites] Nat Protoc. 2006;1(5):2365-76 [17406480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] Pediatr Hematol Oncol. 2007 Mar;24(2):87-99 [17454774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7 [17460043.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1013-20 [17640862.001]
  • [Cites] Pediatr Transplant. 2007 Sep;11(6):584-94 [17663679.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1141-6 [17478638.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1853-61 [17510216.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1439-47 [17468339.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):4249-54 [17785865.001]
  • [Cites] Aging Cell. 2007 Oct;6(5):639-47 [17874998.001]
  • [Cites] Hum Mutat. 2007 Dec;28(12):1178-82 [17647292.001]
  • [Cites] Exp Hematol. 2007 Dec;35(12):1777-81 [17697745.001]
  • [Cites] Am J Hum Genet. 2008 Feb;82(2):501-9 [18252230.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):189-92 [11918553.001]
  • [Cites] Acta Haematol. 2002;107(4):208-12 [12053148.001]
  • [Cites] Science. 2002 Jul 26;297(5581):565-9 [12142527.001]
  • [Cites] J Pediatr. 2002 Aug;141(2):259-65 [12183724.001]
  • [Cites] J Pediatr. 2002 Aug;141(2):266-70 [12183725.001]
  • [Cites] Pediatr Res. 2002 Sep;52(3):377-81 [12193671.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):280-4 [12355086.001]
  • [Cites] Ann Hematol. 2002 Oct;81(10):566-9 [12424537.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6405-9 [12438224.001]
  • [Cites] Blood. 2003 Jan 1;101(1):358-62 [12393549.001]
  • [Cites] Blood. 2003 Jan 1;101(1):375-6 [12485943.001]
  • [Cites] Leukemia. 2003 Feb;17(2):401-10 [12592340.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):836-45 [12614219.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):847-50 [12748659.001]
  • [Cites] Blood. 2003 Jul 15;102(2):514-6 [12623835.001]
  • [Cites] Blood. 2003 Aug 1;102(3):916-8 [12676774.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Cytometry A. 2003 Sep;55(1):1-6 [12938182.001]
  • [Cites] Hum Immunol. 2003 Sep;64(9):896-901 [12941546.001]
  • [Cites] Eur J Pediatr. 2003 Dec;162(12):863-7 [14648217.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):507-10 [14975611.001]
  • [Cites] Acta Haematol. 2004;111(3):125-31 [15034232.001]
  • [Cites] Nat Genet. 2004 May;36(5):447-9 [15098033.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3317-26 [15161685.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):63-71 [15198733.001]
  • [Cites] Hepatology. 2004 Jul;40(1):80-6 [15239089.001]
  • [Cites] Leuk Res. 2004 Oct;28(10):1001-4 [15289009.001]
  • [Cites] Leuk Res. 2004 Oct;28(10):1013-21 [15289012.001]
  • [Cites] Br J Haematol. 2004 Sep;126(5):682-5 [15327519.001]
  • [Cites] Br J Haematol. 2004 Oct;127(1):105-13 [15384984.001]
  • [Cites] Eur J Haematol. 2004 Nov;73(5):351-8 [15458514.001]
  • [Cites] J Med Genet. 1992 Sep;29(9):673-5 [1404302.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 Nov;14(4):297-304 [1456394.001]
  • [Cites] Leukemia. 2005 Apr;19(4):644-51 [15716989.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):881-90 [15865944.001]
  • [Cites] Blood Cells Mol Dis. 2005 May-Jun;34(3):257-63 [15885610.001]
  • [Cites] Curr Opin Genet Dev. 2005 Jun;15(3):249-57 [15917199.001]
  • [Cites] Exp Gerontol. 2005 May;40(5):363-8 [15919587.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] Blood. 2005 Jul 15;106(2):531-3 [15811960.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10 [16085011.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):662-4 [16112303.001]
  • [Cites] Leuk Res. 2005 Oct;29(10):1131-9 [16111531.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2100-10 [16166375.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6699-711 [16170178.001]
  • [Cites] Int J Hematol. 2005 Oct;82(3):184-9 [16207588.001]
  • [Cites] Twin Res Hum Genet. 2005 Oct;8(5):433-9 [16212832.001]
  • [Cites] Transplantation. 2005 Oct 15;80(7):969-76 [16249747.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:96-103 [16304365.001]
  • [Cites] Bone Marrow Transplant. 2005 Dec;36(12):1103-5; author reply 1105 [16205731.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):977-89 [16364206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9203-8 [10922071.001]
  • [Cites] Hypertension. 2000 Aug;36(2):195-200 [10948077.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3991-4 [11090091.001]
  • [Cites] Psychoneuroendocrinology. 2006 Apr;31(3):277-87 [16298085.001]
  • [Cites] Hum Genet. 2006 Apr;119(3):344-50 [16440201.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2680-5 [16332973.001]
  • [Cites] Exp Hematol. 2006 May;34(5):664-71 [16647572.001]
  • [Cites] Int J Hematol. 2006 Apr;83(3):275-6 [16720563.001]
  • [Cites] Transfusion. 2006 Jun;46(6):1038-43 [16734822.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):266-72 [16755224.001]
  • [Cites] Curr Pharm Biotechnol. 2006 Jun;7(3):171-83 [16789902.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):167-77 [16822459.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):178-88 [16822460.001]
  • [Cites] Blood Cells Mol Dis. 2006 Sep-Oct;37(2):134-6 [16934504.001]
  • [Cites] Aging Cell. 2006 Oct;5(5):361-5 [16856882.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] Hum Mol Genet. 2007 Jul 1;16(13):1619-29 [17507419.001]
  • [Cites] J Nippon Med Sch. 2007 Jun;74(3):202-9 [17625368.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 3;341(1):128-31 [16412982.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):635-40 [16303830.001]
  • [Cites] Am J Hum Genet. 2006 Mar;78(3):480-6 [16400618.001]
  • (PMID = 18160098.001).
  • [ISSN] 0047-6374
  • [Journal-full-title] Mechanisms of ageing and development
  • [ISO-abbreviation] Mech. Ageing Dev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 107
  • [Other-IDs] NLM/ NIHMS41596; NLM/ PMC2278290
  •  go-up   go-down


39. De Re V, De Vita S, Sansonno D, Toffoli G: Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. Blood; 2008 Jun 15;111(12):5760
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development.
  • [MeSH-major] Autoimmune Diseases / epidemiology. Cryoglobulinemia / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • (PMID = 18544704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Martín-Hernández J, Balle Sørensen A, Pedersen FS: Non-identical patterns of proviral insertions around host transcription units in lymphomas induced by different strains of murine leukemia virus. Virology; 2006 Sep 15;353(1):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Altogether, our results strongly emphasize the importance of host genetic background and virus type for retroviral insertion mutagenesis screens and suggest that different types of MLV may favor specific genomic regions and orientations in order exert optimal effect on target gene expression during lymphoma induction and development.
  • [MeSH-major] Leukemia Virus, Murine / genetics. Lymphoma, B-Cell / genetics. Lymphoma, T-Cell / genetics. Proviruses / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790256.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH: Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol; 2006 Aug;10(4):230-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case involves diffuse, bilateral involvement of the kidneys by non-Hodgkin's lymphoma.
  • The patient's renal function improved dramatically after the initiation of chemotherapy, clearly linking the development of ARF to the malignant process.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney / pathology. Leukemia, Plasma Cell / complications. Leukemic Infiltration. Lymphoma, Non-Hodgkin / complications

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844565.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 4Z8R6ORS6L / Thalidomide; 63CZ7GJN5I / Allopurinol; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


42. Rosato RR, Grant S: Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets; 2005 Aug;9(4):809-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early clinical results suggest a potentially useful role for HDACIs in the treatment of certain forms of lymphoma (e.g., cutaneous T cell lymphoma) and acute leukaemia.
  • Aside from providing critical insights into the mechanism of action of HDACIs in neoplastic disease, these findings may provide a foundation for the rational development of combination studies, involving HDACIs in combination with either conventional cytotoxic drugs as well as more novel targeted agents.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083344.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61774; United States / NCI NIH HHS / CA / CA63753; United States / NCI NIH HHS / CA / CA93738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 194
  •  go-up   go-down


43. Gupta S, Gupta R, Singh S, Gupta K, Kudesia M: Nuclear morphometry and texture analysis of B-cell non-Hodgkin lymphoma: utility in subclassification on cytosmears. Diagn Cytopathol; 2010 Feb;38(2):94-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and texture analysis of B-cell non-Hodgkin lymphoma: utility in subclassification on cytosmears.
  • Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid neoplasms and accurate subclassification is an essential prerequisite for proper management of patients.
  • These results are promising for further studies on this subject and development of automated cytodiagnosis.
  • [MeSH-major] Cell Nucleus / ultrastructure. Cytodiagnosis / methods. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / ultrastructure

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688760.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


44. Ogura M: Current treatment strategy and new agents in mantle cell lymphoma. Int J Hematol; 2010 Jul;92(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment strategy and new agents in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is a well-recognized lymphoma subtype that accounts for about 5% of all patients with non-Hodgkin lymphoma.
  • In recent years, new insights into the biology of MCL have been obtained which have provided the rationale for the development of novel therapeutic strategies.
  • [MeSH-major] Lymphoma, Mantle-Cell / therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1075-82 [7849295.001]
  • [Cites] Adv Anat Pathol. 1998 Nov;5(6):376-98 [10095879.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):503-11 [12841390.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3062-8 [8674063.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1807-14 [14615373.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):283-90 [14760123.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1460-8 [15084619.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5213-8 [19770379.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4 [17875757.001]
  • [Cites] J Clin Oncol. 2010 Apr 20;28(12):2085-93 [20308665.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):179-84 [17991293.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Cancer Immunol Immunother. 2007 Oct;56(10):1551-63 [17310380.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]
  • [Cites] Cancer. 2010 Jan 1;116(1):106-14 [19890959.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1288-94 [11870171.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):369-81 [16633365.001]
  • [Cites] Science. 2008 Aug 15;321(5891):974-7 [18703743.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4776-89 [16034054.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):953-63, ix [18954745.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • [Cites] Br J Haematol. 2004 Jan;124(2):130-40 [14687022.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):793-800 [12614212.001]
  • [Cites] Leukemia. 2007 Jan;21(1):30-6 [17096016.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):337-42 [11377294.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2687-93 [18625886.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7021-5 [7624362.001]
  • (PMID = 20532841.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Hosokawa Y: Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. Apoptosis; 2005 Jan;10(1):25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma.
  • At least three distinct chromosomal translocations, t(11;18)(q21;q21), t(1;14)(p22;q32) and t(14;18)(q32;q21) involving the API2 (also known as c-IAP2)-MALT1 fusion protein, BCL10, and MALT1, respectively, have been implicated in the molecular pathogenesis of mucosa associated lymphoid tissue (MALT) lymphoma.
  • This stability of API2-MALT1 may thus result in inappropriate nuclear factor (NF)-kappaB activation, thereby contributing to the pathogenesis of MALT lymphoma.
  • Further studies can be expected to stimulate research into the development of therapeutic drugs that specifically inhibit the antigen receptor signaling-stimulated NF-kappaB activation pathway: such molecule targeting drugs should be useful for interfering with inappropriate proliferation of lymphocytes associated with inflammatory and neoplastic disorders.
  • [MeSH-major] Apoptosis. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 18. Lymphoma, B-Cell, Marginal Zone / genetics. Proteins / metabolism. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711920.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Proteins; 0 / Receptors, Antigen; 0 / Ubiquitin
  • [Number-of-references] 77
  •  go-up   go-down


46. Mullighan CG: Genomic analysis of acute leukemia. Int J Lab Hematol; 2009 Aug;31(4):384-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies have identified multiple novel genetic alterations targeting critical cellular pathways that contribute to leukemogenesis, including alterations of genes regulating lymphoid development, tumor suppressors, apoptosis regulators, and oncogenes.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486196.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 112
  •  go-up   go-down


47. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH, Li-Weber M: The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer; 2007 Oct 15;121(8):1839-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study suggests that Roc derivatives may be promising candidates for the development of new drugs against hematologic malignancies.
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Tubulin / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17565740.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzofurans; 0 / Drugs, Chinese Herbal; 0 / Tubulin; 84573-16-0 / rocaglamide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


48. Hung YM, Chou KJ, Hung SY, Chung HM, Chang JC: De novo malignancies after kidney transplantation. Urology; 2007 Jun;69(6):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No skin cancer or lymphoma was detected in our transplant recipients.
  • Compared with the KT patients without cancer, older age at KT, female recipient, and low educational status were the significant risk factors for the development of de novo cancers in our KT recipients (P <0.05).
  • Older age at KT, female recipient, and low educational status were the significant risk factors for the development of de novo cancers.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572182.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Lu LY, Yu X: The balance of Polo-like kinase 1 in tumorigenesis. Cell Div; 2009 Jan 22;4:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, overexpression of Plk1 is associated with tumor development and could serve as a prognostic marker for many cancers.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2003 Feb 21;299(5610):1228-31 [12595692.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1863-77 [12488480.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Nov;303(2):858-66 [12388673.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32282-93 [12034729.001]
  • [Cites] J Cutan Pathol. 2002 Jul;29(6):354-8 [12135466.001]
  • [Cites] Curr Biol. 2007 Feb 20;17(4):304-15 [17291761.001]
  • [Cites] Curr Biol. 2007 Feb 20;17(4):316-22 [17291758.001]
  • [Cites] Methods Mol Biol. 2007;361:163-85 [17172711.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):60-5 [17208431.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):658-67 [17046232.001]
  • [Cites] Nat Chem Biol. 2006 Nov;2(11):608-17 [17028581.001]
  • [Cites] Nat Chem Biol. 2006 Nov;2(11):618-26 [17028580.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1095-101 [16980960.001]
  • [Cites] Oncology. 2006;70(3):231-7 [16837776.001]
  • [Cites] Mol Biol Cell. 2006 Aug;17(8):3705-16 [16760428.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):589-94 [16865274.001]
  • [Cites] Oncology. 2006;70(2):126-33 [16645325.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):853-64 [16627997.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):781-95 [16465440.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3162-71 [12082631.001]
  • [Cites] EMBO Rep. 2002 Apr;3(4):341-8 [11897663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1984-9 [11854496.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):121-6 [11743651.001]
  • [Cites] J Neurooncol. 2001 May;53(1):1-11 [11678424.001]
  • [Cites] Cancer Lett. 2001 Aug 10;169(1):41-9 [11410324.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):421-4 [11283617.001]
  • [Cites] Pathol Res Pract. 2000;196(11):753-9 [11186170.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):852-4 [11056542.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):332-6 [10679924.001]
  • [Cites] JAMA. 2000 Jan 26;283(4):479-80 [10659871.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):578-88 [19004025.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5511-7 [18955456.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5504-10 [18955447.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31785-90 [18801727.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(22):6870-6 [18794363.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):119-23 [18615013.001]
  • [Cites] Oncogene. 2008 Jul 3;27(29):4122-7 [18345035.001]
  • [Cites] Science. 2008 Jun 20;320(5883):1655-8 [18566290.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4077-85 [18519666.001]
  • [Cites] Dev Cell. 2008 May;14(5):646-59 [18477449.001]
  • [Cites] Chem Biol. 2008 May;15(5):459-66 [18482698.001]
  • [Cites] Leuk Lymphoma. 2007 Nov;48(11):2179-83 [17943598.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):223-34 [18320067.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10148-58 [17981789.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):894-903 [17912263.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):4024-36 [17671160.001]
  • [Cites] Genes Dev. 2007 Sep 1;21(17):2205-19 [17785528.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):379-93 [17426725.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):450-9 [17267659.001]
  • [Cites] Pancreatology. 2005;5(2-3):259-65 [15855824.001]
  • [Cites] Nat Cell Biol. 2006 Feb;8(2):180-7 [16378098.001]
  • [Cites] Curr Biol. 2005 Nov 8;15(21):R880-2 [16271861.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5644-50 [16237758.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):883-8 [16025114.001]
  • [Cites] Trends Cell Biol. 2005 Jun;15(6):303-11 [15953548.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):978-85 [15761500.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):275-86 [15766665.001]
  • [Cites] Oncogene. 2005 Jan 10;24(2):287-91 [15640844.001]
  • [Cites] Oncogene. 2005 Jan 10;24(2):267-76 [15640842.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):225-31 [15621805.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Nov 15;201(1):66-83 [15519609.001]
  • [Cites] Trends Biochem Sci. 1999 Apr;24(4):136-41 [10322418.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):687-92 [10493949.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2794-7 [10383133.001]
  • [Cites] Hepatology. 1999 May;29(5):1479-85 [10216132.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):430-9 [9914375.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):424-9 [9914374.001]
  • [Cites] J Cell Biol. 1998 Nov 2;143(3):659-71 [9813088.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 20;239(2):377-85 [9344838.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):397-405 [9177283.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):543-9 [9053852.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 2):1701-13 [8991084.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19402-8 [8702627.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21086-91 [7673138.001]
  • [Cites] J Cell Biol. 1995 Jun;129(6):1617-28 [7790358.001]
  • [Cites] J Cell Sci. 1994 Jun;107 ( Pt 6):1509-17 [7962193.001]
  • [Cites] Cell Growth Differ. 1994 Mar;5(3):249-57 [8018557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1736-40 [8127874.001]
  • [Cites] Nature. 1993 Jun 17;363(6430):637-40 [8510757.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5901-11 [15221005.001]
  • [Cites] Prostate. 2004 Aug 1;60(3):240-5 [15176053.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):862-72 [15173270.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):641-6 [15141022.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):815-21 [14970859.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):414-8 [14735186.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54 [14625535.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5757-68 [14592974.001]
  • [Cites] Cell. 2003 Oct 3;115(1):83-95 [14532005.001]
  • [Cites] Dev Cell. 2003 Jul;5(1):113-25 [12852856.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94 [12732729.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):148-52 [12708489.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • (PMID = 19161615.001).
  • [ISSN] 1747-1028
  • [Journal-full-title] Cell division
  • [ISO-abbreviation] Cell Div
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA132755; United States / NCI NIH HHS / CA / CA130899-02; United States / NCI NIH HHS / CA / R01 CA130899; United States / NCI NIH HHS / CA / CA132755-03; United States / NCI NIH HHS / CA / R01 CA132755-03; United States / NCI NIH HHS / CA / R01 CA130899-02
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2642809
  •  go-up   go-down


50. Zhang H, Yang JH, Zheng YS, Zhang P, Chen X, Wu J, Xu L, Luo XQ, Ke ZY, Zhou H, Qu LH, Chen YQ: Genome-wide analysis of small RNA and novel MicroRNA discovery in human acute lymphoblastic leukemia based on extensive sequencing approach. PLoS One; 2009;4(9):e6849
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, GO "biological process" classifications revealed that a set of significantly abnormally expressed miRNAs are associated with disease relapse, which implies that these dysregulated miRNAs might promote the progression of ALL by regulating genes involved in the pathway of the disease development.
  • [MeSH-major] Gene Expression Regulation, Leukemic. MicroRNAs / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. RNA / genetics. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2454-9 [15665081.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genes Dev. 2003 Apr 15;17(8):991-1008 [12672692.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1790-7 [12721256.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):891-2 [12724301.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):2911-7 [15217813.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] RNA. 2005 May;11(5):578-91 [15840812.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Neoplasma. 2005;52(4):318-24 [16059649.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Bioinformatics. 2006 Feb 15;22(4):500-3 [16357029.001]
  • [Cites] Curr Biol. 2006 Mar 7;16(5):460-71 [16458514.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Nucleic Acids Res. 2006;34(11):3338-44 [16820533.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1289-98 [16954537.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1193-207 [17174894.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3475-86 [17182872.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Hematology. 2007 Feb;12(1):39-43 [17364991.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6031-43 [17616659.001]
  • [Cites] Nucleic Acids Res. 2007;35(17):5944-53 [17726050.001]
  • [Cites] Braz J Med Biol Res. 2007 Nov;40(11):1435-40 [17934639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Curr Biol. 2008 Jan 22;18(2):147-51 [18207740.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2300-9 [18056841.001]
  • [Cites] Leukemia. 2008 Feb;22(2):330-8 [17989717.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Genome Res. 2008 Apr;18(4):610-21 [18285502.001]
  • [Cites] Nat Struct Mol Biol. 2008 Apr;15(4):354-63 [18376413.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):407-15 [18392026.001]
  • [Cites] Genome Res. 2008 Jun;18(6):957-64 [18469162.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1274-8 [17989710.001]
  • [Cites] Genes Dev. 2008 Oct 15;22(20):2773-85 [18923076.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1787-97 [18849523.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):248-52 [18729857.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Blood. 2002 Feb 1;99(3):825-33 [11806983.001]
  • (PMID = 19724645.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2731166
  •  go-up   go-down


51. Dalmau J: [Limbic encephalitis and variants related to neuronal cell membrane autoantigens]. Rinsho Shinkeigaku; 2008 Nov;48(11):871-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is due in part to the development of clinical diagnostic criteria and identification of antibodies directed against two broad categories of antigens:.
  • While the disorders related to the first category of antibodies associate with cancer (lung, testis and other), prominent brain infiltrates of T-cells, and limited response to treatment, the disorders related to the second category of antibodies associate with other tumors (thymoma. teratoma, Hodgkin's lymphoma), appear to be antibody-mediated, and respond better to immunotherapy.

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19198103.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Autoantigens; 0 / DPYSL5 protein, human; 0 / ELAV Proteins; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins; 0 / Potassium Channels, Voltage-Gated; 0 / Receptors, N-Methyl-D-Aspartate
  • [Number-of-references] 5
  •  go-up   go-down


52. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW: Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem; 2006 Feb 9;49(3):1165-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
  • Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function, is described.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16451081.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(3-dimethylamino-1-phenylsulfanylmethylpropylamino)-N-(4-(4,4-dimethylpiperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide; 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Piperidines; 0 / Serum Albumin; 0 / Sulfonamides; 0 / bcl-X Protein; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


53. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW: Role of Kruppel-like factors in leukocyte development, function, and disease. Blood; 2010 Nov 25;116(22):4404-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Kruppel-like factors in leukocyte development, function, and disease.
  • The Krüppel-like transcription factor (KLF) family participates in diverse aspects of cellular growth, development, differentiation, and activation.
  • Indeed, KLFs have been implicated in subtypes of leukemia, lymphoma, autoimmunity, and in acute and chronic inflammatory disease states, such as atherosclerosis, diabetes, and airway inflammation, raising the possibility that KLFs and their upstream signals are of therapeutic interest.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 15;27(24):4807-15 [10572182.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1169-74 [10582345.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):167-75 [10851463.001]
  • [Cites] Blood. 2001 May 1;97(9):2625-32 [11313251.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29299-306 [11375995.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):667-8 [11477398.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):698-704 [11477405.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2563-6 [11752579.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30055-65 [12050170.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1689-98 [12176889.001]
  • [Cites] Exp Cell Res. 2002 Nov 15;281(1):19-27 [12441126.001]
  • [Cites] Genome Biol. 2003;4(2):206 [12620113.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):2196-208 [12682370.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):14812-9 [12590140.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4492-9 [12576331.001]
  • [Cites] Blood Cells Mol Dis. 2003 Sep-Oct;31(2):229-33 [12972030.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18451-6 [14976188.001]
  • [Cites] J Exp Med. 2004 May 17;199(10):1305-15 [15136591.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6002-9 [15342380.001]
  • [Cites] Trends Cardiovasc Med. 2004 Aug;14(6):241-6 [15451516.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8088-96 [15361832.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Dev Biol. 1984 Jul;104(1):172-86 [6428949.001]
  • [Cites] Nature. 1985 Jan 3-9;313(5997):27-32 [3917552.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1985;50:465-73 [3007002.001]
  • [Cites] Cell. 1986 Dec 26;47(6):1025-32 [3096579.001]
  • [Cites] EMBO J. 1992 Oct;11(10):3663-71 [1356762.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2776-86 [7682653.001]
  • [Cites] J Biochem. 1993 Oct;114(4):605-9 [8276776.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Mol Cell Biol. 1995 Feb;15(2):852-60 [7823951.001]
  • [Cites] Nature. 1995 May 25;375(6529):316-8 [7753194.001]
  • [Cites] Nature. 1995 May 25;375(6529):318-22 [7753195.001]
  • [Cites] Nat Immunol. 2008 May;9(5):513-21 [18391955.001]
  • [Cites] Int Immunol. 2008 May;20(5):671-81 [18375530.001]
  • [Cites] Nat Med. 2008 Jun;14(6):656-66 [18500350.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(10):1996-2001 [17904406.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2980-9 [18713968.001]
  • [Cites] Shock. 2008 Sep;30(3):260-6 [18197146.001]
  • [Cites] Circ Res. 2008 Sep 26;103(7):690-3 [18757824.001]
  • [Cites] Nat Immunol. 2008 Dec;9(12):1388-98 [18978794.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):958-69 [19029990.001]
  • [Cites] Semin Immunopathol. 2008 Dec;30(4):383-98 [18925397.001]
  • [Cites] Nat Immunol. 2009 Jun;10(6):618-26 [19412182.001]
  • [Cites] Immunity. 2009 Jul 17;31(1):122-30 [19592277.001]
  • [Cites] J Biol Chem. 2009 Sep 11;284(37):24914-24 [19602726.001]
  • [Cites] Science. 2009 Nov 6;326(5954):867-71 [19892988.001]
  • [Cites] Science. 2010 Feb 26;327(5969):1098-102 [20185720.001]
  • [Cites] Curr Opin Immunol. 2010 Apr;22(2):177-84 [20207529.001]
  • [Cites] J Immunol. 2010 Jun 1;184(11):6060-6 [20427763.001]
  • [Cites] J Clin Invest. 2010 Jun;120(6):1961-70 [20440076.001]
  • [Cites] Cell Stress Chaperones. 2010 Nov;15(6):905-12 [20401760.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] J Immunol. 1999 Oct 1;163(7):3662-7 [10490960.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29500-4 [10506214.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(3):1191-9 [15657444.001]
  • [Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1135-41 [15817882.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1569-76 [16102021.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3060-6 [16116194.001]
  • [Cites] J Biochem. 1995 Jan;117(1):91-5 [7775404.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4907-12 [8532536.001]
  • [Cites] DNA Cell Biol. 1996 May;15(5):347-52 [8924208.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1695-705 [8657145.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] Nature. 1996 Oct 24;383(6602):691-6 [8878477.001]
  • [Cites] Science. 1997 Sep 26;277(5334):1986-90 [9302292.001]
  • [Cites] Genes Dev. 1997 Nov 15;11(22):2996-3006 [9367982.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1026-31 [9422764.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):967-71 [9486966.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9500-5 [9689109.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5129-40 [9724649.001]
  • [Cites] Transgenic Res. 1998 Jul;7(4):229-38 [9859212.001]
  • [Cites] Immunity. 1999 Jan;10(1):93-103 [10023774.001]
  • [Cites] Trends Biochem Sci. 1999 Jun;24(6):236-40 [10366853.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21180-5 [10409672.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):49-53 [16338128.001]
  • [Cites] Genomics. 2006 Apr;87(4):474-82 [16460907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6653-8 [16617118.001]
  • [Cites] Nature. 2006 Jul 20;442(7100):299-302 [16855590.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2683-90 [17101733.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):253-66 [17074812.001]
  • [Cites] Blood. 2007 Jan 15;109(2):747-55 [16954505.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5496-504 [17442931.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12590-7 [17337447.001]
  • [Cites] Immunity. 2007 Jun;26(6):726-40 [17582345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13420-5 [17673551.001]
  • [Cites] Mol Immunol. 2008 Jan;45(2):362-75 [17681603.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4679-84 [17878366.001]
  • [Cites] EMBO J. 2007 Sep 19;26(18):4138-48 [17762869.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6808-19 [17982071.001]
  • [Cites] Diabetes Metab. 2007 Nov;33(5):372-8 [17931948.001]
  • [Cites] Nat Immunol. 2008 Mar;9(3):292-300 [18246069.001]
  • [Cites] Nat Immunol. 2008 Mar;9(3):245-53 [18278048.001]
  • [Cites] Cardiovasc Res. 2008 Apr 1;78(1):175-84 [18192240.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5645-52 [18390749.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38247-58 [16169848.001]
  • (PMID = 20616217.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL091076; United States / NHLBI NIH HHS / HL / HL080174; United States / NIDDK NIH HHS / DK / P30DK057521; United States / NHLBI NIH HHS / HL / F32 HL086157; United States / NHLBI NIH HHS / HL / R01 HL080174; United States / NHLBI NIH HHS / HL / R01 HL091076; United States / NIDDK NIH HHS / DK / P30 DK057521; United States / NHLBI NIH HHS / HL / F32 HL088819; United States / NHLBI NIH HHS / HL / F32HL088819; United States / NHLBI NIH HHS / HL / F32HL086157
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Kruppel-Like Transcription Factors
  • [Other-IDs] NLM/ PMC2996110
  •  go-up   go-down


54. Krawczyk CM, Jones RG, Atfield A, Bachmaier K, Arya S, Odermatt B, Ohashi PS, Penninger JM: Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol; 2005 Feb 1;174(3):1472-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The E3 ubiquitin ligase Casitas B cell lymphoma-b (Cbl-b) plays a critical role in the development of autoimmunity and sets the threshold for T cell activation.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661906.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Viral; 0 / Antigens, CD28; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Cell Cycle Proteins; 0 / Cytokines; 0 / Icos protein, mouse; 0 / Immunoglobulin G; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / Peanut Agglutinin; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-vav; 0 / Vav1 protein, mouse; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / Cblb protein, mouse; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


55. Coltman CA Jr, Southwest Oncology Group: The Southwest Oncology Group: progress in cancer research. Semin Oncol; 2008 Oct;35(5):545-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SWOG has contributed to the field of cancer research through both the logistical development of new systems, technologies, statistical methodologies, and training, and through specific tangible contributions to science, addressing the standard of care for almost every adult malignancy.
  • [MeSH-minor] Breast Neoplasms / therapy. Gastrointestinal Neoplasms / therapy. Head and Neck Neoplasms / therapy. Humans. Lung Neoplasms / therapy. Lymphoma / therapy. Urogenital Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929152.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG19241; United States / NCI NIH HHS / CA / CA108964; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA37429; United States / NEI NIH HHS / EY / EY014418; United States / NHLBI NIH HHS / HL / HL071022
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


56. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr; 2009 Jul;155(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate whether children with acute lymphocytic leukemia (ALL) who have development of hyperglycemia during induction may have worse relapse-free (RFS) and overall survival (OS) rates.
  • [MeSH-major] Hyperglycemia / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2009 Jul;155(1):A2 [19559280.001]
  • (PMID = 19394046.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


57. Engelmann A, Speidel D, Bornkamm GW, Deppert W, Stocking C: Gadd45 beta is a pro-survival factor associated with stress-resistant tumors. Oncogene; 2008 Feb 28;27(10):1429-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine genetic alterations that favor the development of stress-resistant tumors in vivo, we took advantage of polyclonal tumors generated after retroviral infection of newborn Elambda-MYC mice, in which the retroviral integration acts as a mutagen to enhance tumor progression.
  • [MeSH-major] Antigens, Differentiation / physiology. Lymphoma, B-Cell / metabolism. Oxidative Stress / physiology. Survival / physiology

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891184.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Gadd45b protein, mouse
  •  go-up   go-down


58. Koturbash I, Pogribny I, Kovalchuk O: Stable loss of global DNA methylation in the radiation-target tissue--a possible mechanism contributing to radiation carcinogenesis? Biochem Biophys Res Commun; 2005 Nov 18;337(2):526-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although genetic alterations during radiation-induced lymphoma- and leukemogenesis are fairly well studied, the role of epigenetic changes has been largely overlooked.
  • Rodent models are valuable tools for identifying molecular mechanisms of lymphoma and leukemogenesis.
  • A widely used mouse model of radiation-induced thymic lymphoma is characterized by a lengthy "pre-lymphoma" period.
  • Delineating molecular changes occurring during the pre-lymphoma period is crucial for understanding the mechanisms of radiation-induced leukemia/lymphoma development.
  • This study is the first report on the radiation-induced epigenetic changes in radiation-target murine thymus during the pre-lymphoma period.
  • The presence of stable DNA hypomethylation in the radiation-target tissue, even though DNA damage resulting from initial genotoxic radiation insult was repaired, suggests of the importance of epigenetic mechanisms in the development of radiation-related pathologies.
  • [MeSH-minor] Animals. DNA Damage / radiation effects. Dose-Response Relationship, Radiation. Lymphoma / metabolism. Lymphoma / pathology. Mice. Thymus Gland / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202973.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens
  •  go-up   go-down


59. Debatin KM: Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic. Klin Padiatr; 2009 Nov-Dec;221(6):332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular cell death research proved to be the key for the development of novel strategies for cancer therapy.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Caenorhabditis elegans. Cell Line, Tumor. Child. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / genetics. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Mitochondria / drug effects. Mitochondria / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Receptors, Death Domain / drug effects. Receptors, Death Domain / genetics. TNF-Related Apoptosis-Inducing Ligand / genetics. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 19890783.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / bcl-2-Associated X Protein
  • [Number-of-references] 45
  •  go-up   go-down


60. Kanno H, Onodera H, Endo M, Maeda F, Chida S, Akasaka T, Sawai T: Vascular lesion in a patient of chronic active Epstein-Barr virus infection with hypersensitivity to mosquito bites: vasculitis induced by mosquito bite with the infiltration of nonneoplastic Epstein-Barr virus-positive cells and subsequent development of natural killer/T-cell lymphoma with angiodestruction. Hum Pathol; 2005 Feb;36(2):212-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular lesion in a patient of chronic active Epstein-Barr virus infection with hypersensitivity to mosquito bites: vasculitis induced by mosquito bite with the infiltration of nonneoplastic Epstein-Barr virus-positive cells and subsequent development of natural killer/T-cell lymphoma with angiodestruction.
  • This report describes a vasculitis and subsequently developing angiodestructive lymphoma in an 11-year-old Japanese-Filipino girl exhibiting mosquito allergy with the background of chronic active Epstein-Barr virus (EBV) infection.
  • Microscopically, the angiocentric or angiodestructive pattern of EBV-positive atypical cells supported the diagnosis of extranodal natural killer/T-cell lymphoma.
  • In contrast to the primary mosquito bite lesion, natural killer/T-cell lymphoma cells exhibited the higher expression of EBV latent membrane protein 1 mRNA and the apparent protein expression detected by immunohistochemistry.
  • [MeSH-major] Culicidae. Epstein-Barr Virus Infections / pathology. Insect Bites and Stings / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin / pathology. Vasculitis, Leukocytoclastic, Cutaneous / pathology


61. Fraga MF, Berdasco M, Ballestar E, Ropero S, Lopez-Nieva P, Lopez-Serra L, Martín-Subero JI, Calasanz MJ, Lopez de Silanes I, Setien F, Casado S, Fernandez AF, Siebert R, Stifani S, Esteller M: Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. Cancer Res; 2008 Jun 1;68(11):4116-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have found that TLE1 undergoes promoter CpG island hypermethylation-associated inactivation in hematologic malignancies, such as diffuse large B-cell lymphoma and AML.
  • TLE1 reintroduction in hypermethylated leukemia/lymphoma cells causes growth inhibition in colony assays and nude mice, whereas TLE1-short hairpin RNA depletion in unmethylated cells enhances tumor growth.
  • These data suggest that TLE1 epigenetic inactivation contributes to the development of hematologic malignancies by disrupting critical differentiation and growth-suppressing pathways.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18519670.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Repressor Proteins; 0 / TLE1 protein, human
  •  go-up   go-down


62. Largaespada DA, Collier LS: Transposon-mediated mutagenesis in somatic cells: identification of transposon-genomic DNA junctions. Methods Mol Biol; 2008;435:95-108
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Traditionally, retroviruses have been used for this purpose, allowing the identification of genes that can cause various forms of leukemia or lymphoma with murine leukemia viruses or mammary cancer with mouse mammary tumor viruses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9191-6 [11481482.001]
  • [Cites] Curr Gene Ther. 2006 Oct;6(5):593-607 [17073604.001]
  • [Cites] PLoS